PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/10, 15/62, 15/56, 9/24, 9/42, C12Q 1/68

A2

(11) International Publication Number: WO 97/43409

(43) International Publication Date: 20 November 1997 (20.11.97)

(21) International Application Number: PCT/DK97/00216

(22) International Filing Date: 12 May 1997 (12.05.97)

(30) Priority Data:
0562/96 10 May 1996 (10.05.96) DK

(71) Applicant *(for all designated States except US)*: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DALBØGE, Henrik [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). DIDERICHSEN, Børge [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). SANDAL, Thomas [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). KAUPPINEN, Sakari [FI/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).

(74) Common Representative: NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD OF PROVIDING NOVEL DNA SEQUENCES

(57) Abstract

The present invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, comprising the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv). Further, the invention also relates novel DNA sequences provided according to the method of the invention and polypeptides with an activity of interest encoded by said novel DNA sequences of the invention.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: Method of providing novel DNA sequences

FIELD OF THE INVENTION

The present invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, novel DNA sequences provided according to the method of the invention, polypeptides with an activity of interest encoded by novel DNA sequences of the invention.

BACKGROUND OF THE INVENTION

The advent of recombinant DNA techniques has made it possible to select single protein components with interesting properties and produce them on a large scale. This represents an improvement over the previously employed production process using microorganisms isolated from nature and producing a mixture of proteins which would either be used as such or separated after the production step.

Since the traditional methods were rather time-consuming, more rapid and less cumbersome methods were developed.

A such technique is described in WO 93/11249 (Novo Nordisk A/S).

The method described in WO 93/11249 comprises the steps of:

a) cloning, in suitable vectors, a DNA library from an organism suspected of producing one or more proteins of interest;

b) transforming suitable yeast host cells with said vectors;

c) culturing the host cells under suitable conditions to express any protein of interest encoding by a clone in the DNA library; and

d) screening for positive clones by determining any activity of a protein expressed in step c).

According to this method it is necessary to prepare a DNA library, comprising complete genes encoding polypeptides with activities of interest. Such a library has traditionally been made on mRNA isolated from micro-organisms which has been cultivated and isolated.

As it is only possible with known methods to cultivate about 2% of the microorganisms known today (*i.e.* cultivable microorganisms), genes encoding polypeptides from a huge number of

microorganisms (*i.e.* un-cultivable microorganisms) are generally difficult to identify and clone on the basis of screening technologies used today, such as the above mentioned.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a method for providing a novel DNA sequence encoding a polypeptide with an activity of interest from micro-organisms without having to cultivate and isolate said micro-organisms.

In the first aspect the invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, comprising the following steps:

i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest,

ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence,

iii) expressing said resulting hybrid DNA sequence,

iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity,

v) isolating the hybrid DNA sequence identified in step iv)

Further, the invention also relates novel DNA sequences provided according to the method of the invention and polypeptides with an activity of interest encoded by said novel DNA sequences of the invention.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the cloning strategy of novel hybrid enzyme sequences.

a is an exact N-terminal consensus primer

a_{rc} is the reverse and complement primer to a

b is a degenerated homologous N-terminal primer

c is a degenerated homologous C-terminal primer

d is an exact C-terminal consensus primer

d_{rc} is a reverse and complement of d

f is an exact reverse and complement C-terminal primer extended with a sequence which includes a SalI restriction recognition site.

e is an exact N-terminal primer extended with a sequence which includes an EcoRI restriction recognition site.

1. (in figure 1)

PCR with primers ab and cd to amplify unknown core genes with an activity of interest.

PCR with primers e and a_{rc} to obtain the N-terminal part of the known gene.

PCR with primers d_{rc} and f to obtain the C-terminal part of the known gene.

2. (in figure 1)

SOE-PCR with primers e and f to link the unknown core gene sequence with the known N- and C-terminal gene sequences and introduction of EcoRI and SalI restriction recognition sites.

3. Restriction enzyme digestion followed by ligation of the novel sequence into an expression vector and transformation into a host cell. Screening of clones expressing the produced gene product with the activity of interest.

Figure 2 shows a part of an alignment of prokaryote xylanases belonging to glycosyl hydrolases family 11.

Figure 3 shows an alignment of the translated DNA sequences of Pulpzyme® (SEQ ID NO 2) and the novel gene sequence found in soil, respectively.

Figure 4 shows a schematically a novel hybrid gene provided according to the invention. Part A and Part C are the known sequences linked to the unknown Part B.

Using Pulpzyme® (SEQ ID NO 1) as the starting sequence:

"1" indicated the first nucleotide of the novel hybrid gene provided according to the invention, "433" and "631" the start and end of the part constituted by the unknown gene sequence and "741" the last nucleotide of the novel hybrid gene sequence.

DEFINITIONS

Prior to discussing this invention in further detail, the following terms will first be defined.

"Homology of DNA sequences or polynucleotides" In the present context the degree of DNA sequence homology is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711)(Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Homologous": The term "homologous" means that one single-stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later (*vide infra*).

Using the computer program GAP (*vide supra*) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, it is in the present context believed that two DNA sequences will be able to hybridize (using low stringency hybridization conditions as defined below) if they mutually exhibit a degree of identity preferably of at least 70%, more preferably at least 80%, and even more preferably at least 85%.

"heterologous": If two or more DNA sequences mutually exhibit a degree of identity which is less than above specified, they are in the present context said to be "heterologous".

"Hybridization:" Suitable experimental conditions for determining if two or more DNA sequences of interest do hybridize or not is herein defined as hybridization at low stringency as described in detail below.

A suitable experimental low stringency hybridization protocol between two DNA sequences of interest involves presoaking of a filter containing the DNA fragments to hybridize

in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 μg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a concentration of 10ng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13), ^{32}P-dCTP-labeled (specific activity > 1 x 10^9 cpm/μg) probe (DNA sequence) for 12 hours at ca. 45°C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at least 50°C, more preferably at least 55°C, and even more preferably at least 60°C (high stringency).

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a x-ray film.

"Alignment": The term "alignment" used herein in connection with a alignment of a number of DNA and/or amino acid sequences means that the sequences of interest is aligned in order to identify mutual/common sequences of homology/identity between the sequences of interest. This procedure is used to identify common "conserved regions" (vide infra), between sequences of interest. An alignment may suitably be determined by means of computer programs known in the art, such as ClusterW or PILEUP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711)(Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Conserved regions:" The term "conserved region" used herein in connection with a "conserved region" between DNA and/or amino acid sequences of interest means a mutual common sequence region of the sequences of interest, wherein there is a relatively high degree of sequence identity between the sequences of interest. In the present context a conserved region is preferably at least 10 base pairs (bp)/ 3 amino acids(a.a), more preferably at least 20 bp/ 7 a.a., and even more preferably at least 30 bp/ 10 a.a..

Using the computer program GAP (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer

Group, 575 Science Drive, Madison, Wisconsin, USA 53711)(Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453) (vide supra) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the degree of DNA sequence identity within the conserved region is preferably of at least 80%, more preferably at least 85%, more preferably at least 90%, and even more preferably at least 95%.

"Sequence overlap extension PCR reaction (SOE-PCR)": The term "SOE-PCR" is a standard PCR reaction protocol known in the art, and is in the present context defined and performed according to standard protocols defined in the art ("PCR A practical approach" IRL Press, (1991)).

"primer": The term "primer" used herein especially in connection with a PCR reaction is an oligonucleotide (especially a "PCR-primer") defined and constructed according to general standard specification known in the art ("PCR A practical approach" IRL Press, (1991)).

"A primer directed to a sequence:" The term "a primer directed to a sequence" means that the primer (preferably to be used in a PCR reaction) is constructed so it exhibits at least 80% degree of sequence identity to the sequence part of interest, more preferably at least 90% degree of sequence identity to the sequence part of interest, which said primer consequently is "directed to". The primer is designed in order to specifically anneal at the region at a given temperature it is directed towards. Especially identity at the 3' end of the primer is essential for the function of the polymerase, i.e. the ability of a polymerase to extend the annealed primer.

"Polypeptide" Polymers of amino acids sometimes referred to as protein. The sequence of amino acids determines the folded conformation that the polypeptide assumes, and this in turn determines biological properties such as activity. Some polypeptides consist of a single polypeptide chain (monomeric), whilst other comprise several associated polypeptides (multimeric). All enzymes and antibodies are polypeptides.

"Enzyme" A protein capable of catalysing chemical reactions. Specific types of enzymes are a) hydrolases

including amylases, cellulases and other carbohydrases, proteases, and lipases, b) oxidoreductases, c) Ligases, d) Lyases, e) Isomerases, f) Transferases, etc. Of specific interest in relation to the present invention are enzymes used in detergents, such as proteases, lipases, cellulases, amylases, etc.

"known sequence" is the term used for the DNA sequences of which the full length sequence has been sequenced or at least the sequence of one conserved regions is known.

"unknown sequence" is the term used for the DNA sequences amplified directly from uncultivated micro-organisms comprised in *e.g.* a soil sample used as the starting materia. "Full length DNA sequence" means a structural gene sequence encoding a complete polypeptide with an activity of interest.

"un-cultivated" means that the micro-organism comprising the unknown DNA sequence need not be isolated (*i.e.* to provide a population comprising only identical micro-organisms) before amplification (e.g. by PCR).

The term "an activity of interest" means any activity for which screening methods is known.

The term "un-cultivable micro-organisms" defined micro-organisms which can not be cultivated according to methods know in the art.

The term "DNA" should be interpreted as also covering other polynucleotide sequences including RNA.

The term "linking" sequences means effecting a covalent binding of DNA sequences.

The term "hybrid sequences" means sequences of different origin merged together into one sequence.

The term "structural gene sequence" means a DNA sequence coding for a polypeptide with an activity.

The term "natural occurring DNA" means DNA, which has not been subjected to biological or biochemical mutagenesis. By biological mutagenesis is meant "in vivo" mutagenesis, i.e. propagation under controlled conditions in a living organism, such as a "mutator" strain, in order to create genetic diversity. By biochemical mutagenesis is meant "in vitro" mutagenesis, such as error-prone PCR, oligonucleotide directed

site-specific or random mutagenesis etc.

DETAILED DESCRIPTION OF THE INVENTION

It is the object of the present invention to provide a method for providing novel DNA sequences encoding polypeptides with an activity of interest from micro-organisms without having to cultivate said micro-organisms.

The inventors of the present invention have found that PCR-screening using primers designed on the basis of known homologous region, such as conserved regions, can be used for providing novel DNA sequences. Despite the fact that known homologous regions, such as conserved regions, are used for primer designing a vast number of unknown DNA sequences have been provided. This will be described in the following and illustrated in the Examples.

The DNA sequences provided are full length hybrid structural gene sequences encoding complete polypeptides with an activity of interest made up of one unknown sequence and one or two known sequences.

According to the invention it is essential to identify at least two homologous regions, such as conserved regions, in known gene sequences with the activity of interest. One or two selected known structural gene sequence(s) is(are) used as templates (*i.e.* as starting sequence(s)) for finding and constructing novel DNA structural gene sequences with an activity of interest.

Said homologous regions, such as conserved regions, can be identified by alignment of polypeptides with the activity of interest and may *e.g.* be made by the computer program ClustalW or other similar programs available on the market.

<u>One known structural gene as the starting sequence</u>

In the case of using one known structural gene sequence as the starting sequence it will typically be comprised in a plasmid or vector or the like. A part of the sequence between the two identified homologous regions, such as conserved regions, are deleted to avoid contamination by the wild-type structural gene.

The known DNA sequence, with the homologous regions, such as conserved regions, placed at the ends, are linked to an unknown

DNA sequence amplified directly or indirectly from a sample comprising micro-organisms.

The identified homologous regions, such as conserved regions, must have a suitable distance from each other, such as 10 or more base pairs in between. It is preferred to use homologous regions, such as conserved regions, placed in each end of the known structural full length gene.

However, if knowledge about a specific function (*e.g.* active site) of a domain (*i.e.* part of the structural gene sequence) is available it may be advantageous to used conserved regions placed in proximity of and on each side said domain as basis for the PCR amplification to provide novel DNA sequences according to the invention which will be described below in details.

Two known genes as starting sequences

In the case of using two known structural genes as the stating sequences at least one homologous region, such as conserved region, should be identified in each of the two sequences within the polypeptide coding region.

In both case (*i.e.* one or two known genes as starting sequences) the homologous regions, such as conserve regions, should preferably be situated at each end of the structural gene(s) (*i.e.* the sequences encoding the N-terminal end (*i.e.* named Part A on figure 4) and the C-terminal end, respectively (*i.e.* named Part C on figure 4) of the known part of the hybrid polypeptide

In the first aspect the invention relates to a method for providing novel DNA sequences encoding polypeptides with an activity of interest comprises the following steps:

i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest,

ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence,

iii) expressing said resulting hybrid DNA sequence,

iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity,

v) isolating the hybrid DNA sequence identified in step iv)

In step i) the part between the corresponding homologous regions, such as conserved regions, of the unknown structural gene are amplified.

In an embodiment the PCR amplification in step i) is performed using naturally occurring DNA or RNA as template.

In anither embodiment the micro-organism has not been subjected to "in vitro" selection.

The PCR amplification may be performed on a sample containing DNA or RNA from un-isolated micro-organisms. According to the invention no prior knowledge about the unknown sequence is required.

In an embodiment of the invention said 5' and 3' structural gene sequences originate from two different known structural gene sequences encoding polypeptides having the same activity or related activity.

The 5' structural gene sequence and the 3' structural gene sequence may also originate from the same known structural gene encoding a polypeptide with the activity of interest or from two different known structural gene sequences encoding polypeptides having different activities. In the latter case it is preferred that at least one of the starting sequences originates from a known structural gene sequence encoding a polypeptide with the activity of interest.

In a preferred embodiment of the method of the invention the known structural gene is situated in a plasmid or a vector. In said case the method comprises the following steps:

i) PCR amplification of DNA from micro-organisms with PCR primers being homologous to conserved regions of a known gene encoding a polypeptide with an activity of interest,

ii) cloning the obtained PCR product into a gene encoding a polypeptide having said activity of interest, where said gene is not identical to the gene from which the PCR product is obtained, which gene is situated in an expression vector,

iii) transforming said expression vector into a suitable host cell,

iiia) culturing said host cell under suitable conditions,

iv) screening for clones comprising a DNA sequence originated from the PCR amplification in step i) encoding a polypeptide with said activity of interest or a related activity,

v) isolating the DNA sequence identified in step iv).

According to this embodiment one known structural gene sequence is used as the starting sequence. It is to be understood that the PCR product obtained in step i) is cloned into a known gene where a part of the DNA sequence, between the conserved regions, is deleted (*i.e.* cut out) or in an other way substituted with the PCR product. The deleted part of the known gene comprised in the vector may have any suitable size, typically between 10 and 5000 bp, such as from between 10 to 3000 bp.

A general problem is that, when amplifying DNA sequences encoding polypeptides with an activity by PCR, the obtained PCR product (*i.e.* being a part of an unknown gene) does not normally encode a polypeptide with the desired activity of interest.

Therefore, according to the invention the complete full length structural gene, encoding a functional polypeptide, is provided by cloning (*i.e.* by substituting) the PCR product of the unknown structural gene into the known gene situated on the expression vector.

It should be emphasised that the DNA mentioned in step i), to be PCR amplified, need not to comprise a complete gene encoding a functional polypeptide. This is advantageous as only a smaller region of the DNA of the micro-organism(s) in question need to be amplified.

The novel DNA sequences obtained according to the invention consist of the PCR product merged or linked into the known gene, having a number of nucleotides between the conserved regions deleted. The PCR product is inserted into the known gene between the two ends of the cut open vector by overlapping homologous regions of about 10 to 200 bp at each end of the vector.

The resulting novel hybrid DNA sequences constitute complete full length genes comprising the PCR product and encodes a polypeptide with the activity of interest.

It is to be understood that it is not absolutely necessary to delete a part of the known gene sequence. However, if a part of the known gene sequence is not deleted re-ligation results in that the wild-type activity of the known gene is regained and thus give a high number of wild-type background clones, which would make the screening procedure more time consuming and cumbersome.

The PCR amplification in step i) can be performed on both cultivable and uncultivable micro-organisms by directly or indirectly amplification of DNA from the genomic material of the micro-organisms in the environment (*i.e.* directly or indirectly from the sample taken).

The micro-organisms

The micro-organisms from which the unknown DNA sequences are derived may be micro-organisms which cannot today be cultivated. This is possible as the DNA sequences can be amplified by PCR without the need first to cultivate and isolate the micro-organisms comprising the unknown DNA sequence(s).

It is however to be understood that the method of the invention can also be used for providing novel DNA sequences derived from micro-organisms which can be cultivated.

Therefore the method of the invention can be performed on both cultivable and un-cultivable organisms as the micro-organisms in question do not, according to the method of the invention, need to be cultivated and isolated from, *e.g.* the soil sample, comprising micro-organisms.

Starting material

The starting material, *i.e.* the sample comprising micro-organisms with the target unknown DNA sequences, may for instance be an environmental samples of plant or soil material, animal or insect dung, insect gut, animal stomach, a marine sample of sea or lake water, sewage, waste water, etc., comprising one or, as in most case, a vast number of different cultivable and/or un-cultivable micro-organisms.

If the genomic material of the micro-organisms are readily accessible the PCR amplification may be performed directly on the

sample. In other cases a pre-purification and isolation procedure of the genomic material is needed.

Smalla et al. (1993), J. Appl. Bacteriol 74, p. 78-85; Smalla et al. (1993), FEMS Microbiol Ecol 13, p. 47-58, describes how to extract DNA directly from micro-organisms in the environment (*i.e.* the sample).

Borneman et al. (1996), Applied and Environmental Microbiology, 1935-1943, describes a method for extracting DNA from soils.

A commercially available kit for isolating DNA from environmental samples, such as *e.g.* soils, can be purchased from BIO 101 under the tradename FastDNA® SPIN Kit.

Seamless™ Cloning kit (cataloge no. Stratagene 214400) is a commercial kit suitable for cloning of any DNA fragment into any desired location *e.g.* a vector, without the limitation of naturally occurring restriction sites.

PCR amplification of DNA and/or RNA of micro-organisms in the environment is described by Erlich, (1989), PCR Technology. Principles and Applications for DNA Amplification, New York/London, Stockton Press; Pillai, et al., (1991), Appl. Environ. Microbiol, 58, p. 2712-2722)

Other methods for PCR amplifying microbial DNA directly from a sample is described in Molecular Microbial Ecology Manual, (1995), Edited by Akkermans et al.. A suitable method for microbial DNA from soil samples is described by Jan Dirk van Elsas et al., (1995), Molecular Microbial Ecology Manual 2.7.2, p. 1-10.

Stein et al., (1996), J. Bacteriol., Vol. 178, No. 2, p. 591-599, describes a method for isolating DNA from un-cultivated prokaryotic micro-organisms and cloning DNA fragments therefrom.

The PCR primers being homologous to conserved regions of the known gene encoding a polypeptide with an activity of interest are synthesized according to standard methods known in the art (see for instance EP 684 313 from Hoffmann-La Roche AG) on the basis of knowledge to conserved regions in the polypeptide with the activity of interest.

Said PCR primers may be identical to at least a part of the conserved regions of the known gene. However, said primers may advantageously be synthisized to differ in one or more positions.

Further, a number of different PCR primers homologous to the conserved regions may be used at the same time in step i) of the method of the invention.

The cultivable or uncultivable micro-organisms may be both prokaryotic organisms such as bacteria, or eukaryotic organisms including algae, fungi and protozoa.

Examples of un-cultivable organisms include, without being limited thereto, extremophiles and plantonic marine organisms etc.

The group of cultivable organisms include bacteria, fungal organisms, such as filamentous fungi or yeasts.

In the case of using DNA from cultivable organisms the PCR amplification in step i) may be performed on one or more polynucleotides comprised in a vector, plasmid or the like, such as on a cDNA library.

Specific examples of "an activity of interest" include enzymatic activity and anti-microbial activity.

In a preferred embodiment of the invention the activity of interest is an enzymatic activity, such as an activity selected from the group comprising of phosphatases oxidoreductases (E.C. 1), transferases (E.C. 2); hydrolases (E.C. 3), such as esterases (E.C. 3.1), in particular lipases and phytase; such as glucosidases (E.C. 3.2), in particular xylanase, cellulases, hemicellulases, and amylase, such as peptidases (E.C. 3.4), in particular proteases; lyases (E.C. 4); isomerases (E.C. 5); ligases (E.C. 6).

The host cell used in step iii) may be any suitable cell which can express the gene encoding the polypeptide with the activity of interest. The host cells may for instance be a yeast, such as a strain of *Saccharomyces*, in particular *Saccharomyces cerevisiae*, or a bacteria, such as a strain of *Bacillus*, in particular of *Bacillus subtilis*, or a strain *Escherichia coli*.

Clones found to comprise a DNA sequence originated from the PCR amplification in step i) may be screened for any activity of interest. Examples of such activities include enzymatic activity,

anti-microbial activity or biological activities.

The polypeptide with the activity of interest may then be tested for a desired performance under specific conditions and/or in combination with *e.g.* chemical compounds or agent. In the case where the polypeptide is an enzyme *e.g.* the wash performance, textile dyeing, hair dyeing or bleaching properties, effect in feed or food may be assayed to identify polypeptides with a desired property.

Identification of conserved regions of prokaryote xylanases

Figure 2 shows an alignment of prokaryote xylanases from the family 11 of glycosyl hydrolases (B. Henrissat, Biochem J, 280:309-316 (1991)). There are several region where the amino acids are identical or almost identical, *i.e.* conserved regions.

Examples of homologous regions or conserved regions in prokaryotic xylanases from family 11 of glycosyl hydrolases (B. Henrissat, (1991), Biochem J 280:309-316) are the sequence "DGGTYDIY" (SEQ ID NO 3) position 145-152, "EGYQSSG" (SEQ ID NO. 4) position 200-206 in the upper polypeptide shown in figure 2.

Based on *e.g.* said regions degenerated PCR primers can be designed. These degenerated PCR primers can amplify unknown DNA sequences coding for polypeptides (*i.e.* referred to as PCR products below) which are homologous to the known polypeptide(s) in question (*i.e.* SEQ ID NO 2) flanked by the conserved regions.

The PCR products obtained can be cloned into a plasmid and sequenced to check if they contain conserved regions and are homologous to the known structural gene sequence(s).

A homologous PCR product is however not a guarantee that the sequence code for a part of a polypeptide having the desired activity of interest.

Therefore, according to the method of the invention one or more steps selecting DNA sequences encoding polypeptides having the activity of interest follow the construction of the novel hybrid DNA sequences.

The unknown DNA sequences

When method of the invention is performed on DNA from samples of uncultivated organisms it is advantageous to screen for gene products with the activity of interest.

A suitable method for doing this is to link the PCR products with a 5' sequence upstream the first conserved region DNA sequence and the 3' sequence downstream the second consensus, respectively, from the known gene sequence.

The product of the unknown gene sequence linked to an N-terminal and C-terminal part of a known gene product is then screened for the activity of interest.

The N-terminal and C-terminal parts can originate from the same gene product but it is not a prerequisite for activity. The N-terminal and C-terminal parts may also originate from different gene products as long as they originate from the same polypeptide family *e.g.* the same glycosyl hydrolases.

A method to link the unknown gene sequence with the known sequences is to clone the PCR product into a known gene, encoding a polypeptide having the activity of interest, which have had the sequences between the conserved regions removed.

Another method is merging the PCR product, the N-terminal part and the C-terminal part by SOE-PCR (splicing by overlap extension PCR) *e.g.* as shown in figure 1 and described in detail in Example 1. Other methods known in the art may also be used.

In a second aspect the invention relates to a novel DNA sequence provided by the method of the invention and the polypeptide encoded by said novel DNA sequence.

MATERIALS AND METHODS

Pulpzyme® is a xylanase derived from *Bacillus sp. AC13*, NCIMB No. 40482. and is described in WO 94/01532 from Novo Nordisk A/S

AZCL Birch xylan (MegaZyme, Australia).

Plasmids:

The Aspergillus expression vector pHD414 is a derivative of the plasmid p775 (described in EP 238 023). The construction of

pHD414 is further described in WO 93/11249.

The 43 kD EG V endoglucanase cDNA from H. insolens (disclosed in WO 91/17243) is cloned into pHD414 in such a way that the endoglucanase gene is transcribed from the TAKA-promoter. The resulting plasmid is named pCaHj418.

Kits

QIAquick PCR Purification Kit Protocol

Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA)

AmpliTaq Gold polymerase (Perkin-Elmer, USA)

Micro-organisms

Bacteria

electromax DH10B *E. coli* cells (GIBCO BRL)

Fungal micro-organisms:

Cylindrocarpon sp.: Isolated from marine sample, the Bahamas

Classification: *Ascomycota, Pyrenomycetes, Hypocreales* unclassified

Fusarium anguioides Sherbakoff IFO 4467

Classification: *Ascomycota, Pyrenomycetes, Hypocreales, Hypocreaceae*

Gliocladium catenulatum Gillman & Abbott CBS 227.48

Classification: *Ascomycota, Pyrenomycetes, Hypocreales, Hypocreaceae*

Humicola nigrescens Omvik CBS 819.73

Classification: *Ascomycota, Pyrenomycetes, Sordariales,* (fam. unclassified)

Trichothecium roseum IFO 5372

Plates

LB-ampicillin plates: 10 g Bacto-tryptone, 5 g Bacto yeast extract, 10 g NaCl, in 1 litre water, 2% agar 0.1% AZCL Birch xylan, 50 microg/ml ampicillin.

Equipment

Applied Biosystems 373A automated sequencer

PCR Amplification

All Polymerase Chain Reactions is carried out under standard conditions as recommended by Perkin-Elmer using AmpliTaq Gold polymerase.

Isolation of Environmental DNA

DNA is isolated from an environmental sample using FastDNA® SPIN Kit for Soil according to the manufacture's instructions.

Methods used in Example 3

Strains and growth conditions

The fungal strains listed above, were streaked on PDA plates containing 0.5 % Avicel, and examined under a microscope to avoid obvious mistakes and contaminations. The strains were cultivated in shake flasks (125 rpm and 26 °C) containing 30ml PD medium (to initiate the growth) and 150ml of BA growth medium for cellulase induction.

The production of cellulases in culture supernatants (typically after 3, 5, 7 and 9 days of growth) was assayed using 0.1 % AZCl-HE-cellulose in a plate assay at pH 3, pH 7 and pH 10. The mycelia were harvested and stored at - 80°C.

Preparation of RNase-free glassware, tips and solutions

All glassware used in RNA isolations were baked at + 250°C for at least 12 hours. Eppendorf tubes, pipet tips and plastic columns were treated in 0.1 % diethylpyrocarbonate (DEPC) in EtOH for 12 hours, and autoclaved. All buffers and water (except Tris-containing buffers) were treated with 0.1 % DEPC for 12 hours at 37°C, and autoclaved.

Extraction of total RNA

The total RNA was prepared by extraction with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M CsCl cushion [Chirgwin, (1979) Biochemistry 18, 5294-5299] using the following modifications. The frozen mycelia was ground in liquid N2 to fine powder with a mortar and a pestle,

followed by grinding in a precooled coffee mill, and immediately suspended in 5 vols of RNA extraction buffer (4 M GuSCN, 0.5 % Na-laurylsarcosine, 25 mM Na-citrate, pH 7.0, 0.1 M ß-mercaptoethanol). The mixture was stirred for 30 min. at RT° and centrifuged (20 min., 10 000 rpm, Beckman) to pellet the cell debris. The supernatant was collected, carefully layered onto a 5.7 M CsCl cushion (5.7 M CsCl, 0.1 M EDTA, pH 7.5, 0.1 % DEPC; autoclaved prior to use) using 26.5 ml supernatant per 12.0 ml CsCl cushion, and centrifuged to obtain the total RNA (Beckman, SW 28 rotor, 25 000 rpm, RT°, 24h). After centrifugation the supernatant was carefully removed and the bottom of the tube containing the RNA pellet was cut off and rinsed with 70 % EtOH. The total RNA pellet was transferred into an Eppendorf tube, suspended in 500 µl TE, pH 7.6 (if difficult, heat occasionally for 5 min at 65 °C), phenol extracted and precipitated with ethanol for 12 h at -20°C (2.5 vols EtOH, 0.1 vol 3M NaAc, pH 5.2). The RNA was collected by centrifugation, washed in 70 % EtOH, and resuspended in a minimum volume of DEPC-DIW. The RNA concentration was determined by measuring OD 260/280.

Isolation of poly(A)+RNA

The poly(A)+ RNAs were isolated by oligo(dT)-cellulose affinity chromatography [Aviv, (1972), Proc. Natl. Acad. Sci. U.S.A. 69, 1408-1412]. Typically, 0.2 g of oligo(dT) cellulose (Boehringer Mannheim, Germany) was preswollen in 10 ml of 1 x column loading buffer (20 mM Tris-Cl, pH 7.6, 0.5 M NaCl, 1 mM EDTA, 0.1 % SDS), loaded onto a DEPC-treated, plugged plastic column (Poly Prep Chromatography Column, Bio Rad), and equilibrated with 20 ml 1 x loading buffer. The total RNA (1-2 mg) was heated at 65 °C for 8 min., quenched on ice for 5 min, and after addition of 1 vol 2 x column loading buffer to the RNA sample loaded onto the column. The eluate was collected and reloaded 2-3 times by heating the sample as above and quenching on ice prior to each loading. The oligo(dT) column was washed with 10 vols of 1 x loading buffer, then with 3 vols of medium salt buffer (20 mM Tris-Cl, pH 7.6, 0.1 M NaCl, 1 mM EDTA, 0.1 % SDS), followed by elution of the poly(A)+ RNA with 3 vols of elution buffer (10 mM Tris-Cl, pH 7.6, 1 mM EDTA, 0.05% SDS)

preheated to + 65 °C, by collecting 500 µl fractions. The OD260 was read for each collected fraction, and the mRNA containing fractions were pooled and ethanol precipitated at -20°C for 12 h. The poly(A)+ RNA was collected by centrifugation, resuspended in DEPC-DIW and stored in 5-10 µg aliquots at -80 °C.

cDNA synthesis

First strand synthesis

Double-stranded cDNA was synthesized from 5 µg of poly(A)+ RNA by the RNase H method (Gubler et al. (1983) Gene 25, 263-269; Sambrook et al.(1989), Molecular Cloning: A Laboratory Manual, 2 Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) using the hair-pin modification. The poly(A)+RNA (5 µg in 5 µl of DEPC-treated water) was heated at 70°C for 8 min. in a pre-siliconized, RNase-free Eppendorph tube, quenched on ice, and combined in a final volume of 50 µl with reverse transcriptase buffer (50 mM Tris-Cl, pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM DTT, Bethesda Research Laboratories) containing 1 mM of dATP, dGTP and dTTP, and 0.5 mM of 5-methyl-dCTP (Pharmacia), 40 units of human placental ribonuclease inhibitor (RNasin, Promega), 1.45 µg of oligo(dT)18- Not I primer (Pharmacia) and 1000 units of SuperScript II RNase H- reverse transcriptase (Bethesda Research Laboratories). First-strand cDNA was synthesized by incubating the reaction mixture at 45 °C for 1 h. After synthesis, the mRNA:cDNA hybrid mixture was gel filtrated through a MicroSpin S-400 HR (Pharmacia) spin column according to the manufacturer´s instructions.

Second strand synthesis

After the gel filtration, the hybrids were diluted in 250 µl of second strand buffer (20 mM Tris-Cl, pH 7.4, 90 mM KCl, 4.6 mM MgCl2, 10 mM (NH4)2SO4, 0.16 mM ßNAD+) containing 200 µM of each dNTP, 60 units of *E. coli* DNA polymerase I (Pharmacia), 5.25 units of RNase H (Promega) and 15 units of E. coli DNA ligase (Boehringer Mannheim). Second strand cDNA synthesis was performed by incubating the reaction tube at 16°C for 2 h, and an additional 15 min at 25°C. The reaction was stopped by addition of EDTA to 20 mM final concentration followed by phenol

and chloroform extractions.

Mung bean nuclease treatment

The double-stranded (ds) cDNA was ethanol precipitated at -20°C for 12 hours by addition of 2 vols of 96% EtOH, 0.2 vol 10 M NH4Ac, recovered by centrifugation, washed in 70% EtOH, dried (SpeedVac), and resuspended in 30 µl of Mung bean nuclease buffer (30 mM NaAc, pH 4.6, 300 mM NaCl, 1 mM ZnSO4, 0.35 mM DTT, 2 % glycerol) containing 25 units of Mung bean nuclease (Pharmacia). The single-stranded hair-pin DNA was clipped by incubating the reaction at 30°C for 30 min, followed by addition of 70 µl 10 mM Tris-Cl, pH 7.5, 1 mM EDTA, phenol extraction, and ethanol precipitation with 2 vols of 96% EtOH and 0.1 vol 3M NaAc, pH 5.2 on ice for 30 min.

Blunt-ending with T4 DNA polymerase

The ds cDNAs were recovered by centrifugation (20 000 rpm, 30 min.), and blunt-ended with T4 DNA polymerase in 30 µl of T4 DNA polymerase buffer (20 mM Tris-acetate, pH 7.9, 10 mM MgAc, 50 mM KAc, 1 mM DTT) containing 0.5 mM each dNTP and 5 units of T4 DNA polymerase (New England Biolabs) by incubating the reaction mixture at +16°C for 1 hour. The reaction was stopped by addition of EDTA to 20 mM final concentration, followed by phenol and chloroform extractions and ethanol precipitation for 12 h at -20°C by adding 2 vols of 96% EtOH and 0.1 vol of 3M NaAc, pH 5.2.

Adaptor ligation, Not I digestion and size selection

After the fill-in reaction the cDNAs were recovered by centrifugation as above, washed in 70% EtOH, and the DNA pellet was dried in SpeedVac. The cDNA pellet was resuspended in 25 µl of ligation buffer (30 mM Tris-Cl, pH 7.8, 10 mM MgCl2, 10 mM DTT, 0.5 mM ATP) containing 2.5 µg non-palindromic BstXI adaptors (1 µg/µl, Invitrogen) and 30 units of T4 ligase (Promega) by incubating the reaction mix at +16°C for 12 h. The reaction was stopped by heating at + 65°C for 20 min, and then on ice for 5 min. The adapted cDNA was digested with Not I restriction enzyme by addition of 20 µl autoclaved water, 5 µl of 10 x Not I restriction enzyme buffer (New England Biolabs) and 50 units

of Not I (New England Biolabs), followed by incubation for 2.5 hours at +37°C. The reaction was stopped by heating the sample at +65°C for 10 min. The cDNAs were size-fractionated by agarose gel electrophoresis on a 0.8% SeaPlaque GTG low melting temperature agarose gel (FMC) in 1 x TBE (in autoclaved water) to separate unligated adaptors and small cDNAs. The gel was run for 12 hours at 15 V, the cDNA was size-selected with a cut-off at 0.7 kb by cutting out the lower part of the agarose gel, and the cDNA was concentrated by running the gel backwards until it appeared as a compressed band on the gel. The cDNA (in agarose) was cut out from the gel, and the agarose was melted at 65°C in a 2 ml Biopure Eppendorph tube (Eppendorph). The sample was treated with agarase by adding 0.1 vol of 10 x agarase buffer (New England Biolabs) and 2 units per 100 µl molten agarose to the sample, followed by incubation at 45°C for 1.5 h. The cDNA sample was phenol and chloroform extracted, and precipitated by addition of 2 vols of 96 % EtOH and 0.1 vol of 3M NaAc, pH 5.2 at - 20°C for 12 h.

EXAMPLES

Example 1

Providing novel DNA sequences encoding polypeptide with xylanase activity

Novel sequences with xylanase activity were provided according to the method of the invention using the glycosyl hydrolase family 11 xylanase derived from *Bacillus sp.* (SEQ ID No 1) as the known structural gene sequence.

Identification of conserved regions by alignment

An amino acid sequence alignment of ten family 11 xylanases revealed at least 3 conserved sequences. Two of these conserved sequences are used to design appropriate PCR primers for amplification of unknown DNA sequences.

The first conserved sequence shown in SEQ ID No. 3 *i.e.* "DGGTYDIY" corresponding to position 433-456 in SEQ ID NO 1.

The second conserved sequence shown in SEQ 4, *i.e.* "EGYQSSG" corresponding to position 631-651 in SEQ ID NO 1.

PCR amplification of the known and unknown partial structural gene sequences

Initially the N-terminal end (*i.e.* Part A) and the C-terminal (*i.e.* Part C) of the known xylanase gene, in which the unknown sequence (*i.e.* Part B) is to be inserted, were amplified by PCR (see figure 4)

Part A was PCR amplified using the two primers (*i.e.* primer e and primer a_{rc}) and as DNA template a plasmid carrying the known xylanase gene (*i.e.* SEQ ID NO 1).

Primer e (shown in SEQ ID NO 5 and figure 1) is an exact N-terminal primer extended with a sequence which included an EcoRI restriction recognition site.

Primer a_{rc} (shown in SEQ ID NO 6 and figure 1) is a reverse and complement sequence primer of position 411-432 in SEQ ID NO 1.

Part C was PCR amplified using the two primers (*i.e.* primer f and primer d_{rc}) mentioned below and as DNA template a plasmid carrying the known xylanase gene.

Primer f is an exact reverse and complement C-terminal primer extended with a sequence which having a SalI restriction recognition site is shown in SEQ ID No. 7.

Primer d_{rc} (SEQ ID NO 8) was designed on the basis of position 651-672 in SEQ ID No. 1.

Part B was PCR amplified using two primers (*i.e.* primer ab and primer cd) and as DNA template DNA purified from a soil sample using the FastDNA® SPIN Kit.

Primer ab (SEQ ID NO 9) has the exact sequence of position 411-432 in SEQ ID 1 extended with degenerated xylanase consensus sequence covering position 433-452 in SEQ ID NO 1

Primer cd (SEQ ID NO: 10) has the exact reverse and complement sequence of position 672-651 in SEQ ID NO 1 extended with degenerated xylanase consensus sequence covering position 650-631 in SEQ ID NO 1.

The N-terminal part of the known xylanase gene (Part A) was PCR amplified for 9 min. at 94°C followed by 30 cycles (45 second at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and finally for 7 min. at 72°C. This gave a PCR product of approx. 450 bp.

The C-terminal part (Part C) of the known xylanase gene was PCR amplified for 9 min. at 94°C followed by 30 cycles (45 seconds at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and finally for 7 min. at 72°C. This gave a PCR product of approx. 100 bp.

The unknown sequences (Part B) was PCR amplified for 9 min. at 94°C followed by 40 cycles(45 seconds at 94°C, 45 seconds at 50°C and 1 min. at 72°C) and finally for 7 min. at 72°C. This gave a PCR product of approx. 260 bp.

The PCR products mentioned above were carefully purify to avoid remains of template DNA which can produce false positive bands in the following SOE-PCR where the products are joined together to form hybrid sequences.

Construction of hybrid sequences

Hybrid sequences containing the N- and C-terminal parts of the known xylanase gene with core part of unknown genes was constructed by splicing by overlap extension PCR (SOE-PCR).

Equal molar amounts of Part A, Part B and Part C PCR products were mixed and PCR amplified under standard conditions except that the reaction was started without any primers.

The reaction started with 9 min. at 94°C followed by 4 cycles (45 seconds at 94°C, 45 seconds at 50°C, 1 min. at 72°C), then primers e and f (SEQ ID No. 5 and 7, respectively) were added, followed by 25 cycles (45 seconds at 94°C, 45 seconds at 50°C, 1 min. at 72°C) and finally 7 min. at 72°C. This gave a SOE-PCR product of the expected size of approx. 770 bp.

Cloning of the hybrids

The SOE-PCR product was purified using the QIAquick PCR Purification Kit Protocol and digested overnight with EcoRI and SalI according to the manufacturers recommendation. The digested product was then ligated into an *E. coli* expression vector overnight at 16°C (in this case a vector where the hybrid gene is under control of a temperature sensitive lamda repressor promoter).

The ligation mixture was transformed into electromax DH10B *E. coli* cells (GIBCO BRL) and plated on LB-ampicillin plates containing 0.1% AZCL Birch xylan. After induction of the promoter (by increasing the temperature to 42°C) xylanase positive colonies were identified as colonies surrounded by a blue halo.

Plasmid DNA was isolated from positive *E. coli* colonies using standard procedures and sequenced with the Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) using an Applied Biosystems 373A automated sequencer according to the manufacturers instructions.

The sequence of a positive clone is shown in SEQ ID NO 11 and the corresponding protein sequence is shown in SEQ ID NO 12.

An alignment of the known xylanase sequence (SEQ ID NO 2) and the novel DNA sequence provided according to the method of the invention can be seen in Figure 3. As can be seen the two protein sequences differs between the two identified conserved regions (*i.e.* SEQ ID NO 3 and SEQ ID NO 4, respectively).

Example 2

Efficiency of the method of the invention

Degenerated primers were designed on the basis of conserved regions identified by alignment of a number of family 5 cellulases and family 10 and 11 xylanases found on the Internet in ExPASy under Prosite (Dictionary of protein sites and patterns).

PCR amplification of a number of unknown structural gene sequences from soil and cow rumen samples were performed with various degenerated primers covering identified conserved region sequences to show how effective the method of the invention is.

The PCR products were cloned into the vector pCR^{tm}II, provided with the original TA cloning kit from Invitrogen. Said vector provides the possibility to make blue-white screening, the white colonies were selected and the inserts were sequenced.

When editing the Sequence Listing below all sequences outside the two EcoRI sites in the polylinker were removed.

Therefore all sequences have a small additional part of the polylinker (i.e. from the EcoRI site to the TT overhang) in both ends of the sequences. These extensions are "GAATTCGGCT" and "AAGCCG".

1. PCR primers were designed on the basis of identified conserved regions #1 GWNLGN and #2 (E/D)HLIFE of cellulases from the glycosyl hydrolase family 5 aiming to provide novel sequences with cellulase activity.

SEQ ID NO 13 and 14 show the sequences obtained from a soil sample. SEQ ID NO 15 and 16 show the sequences obtained from a cow rumen sample.

2. PCR primers were designed on the basis of identified conserved regions #1 GWNLGN and #3 RA(S/T)GGNN of cellulases from the glycosyl hydrolase family 5 aiming to provide novel sequences with cellulase activity.

SEQ ID NO 17 to 19 show the sequences obtained from a cow rumen sample.

3. PCR primers were designed on the basis of identified conserved regions #2 (E/D)HLIFE and #3 RA(S/T)GGNN of cellulases from the glycosyl hydrolase family 5 aiming to provide novel sequences with cellulase activity.

SEQ ID NO 20 to 22 show the sequences obtained from a cow rumen sample.

4. PCR primers were designed on the basis of identified conserved regions #4 HTLVWH and #5 WDVVNE of xylanases from the glycosyl hydrolase family 10 aiming to provide novel sequences with xylanase activity.

SEQ ID NO 23 to 28 show the sequences obtained from a cow rumen sample.

5. PCR primers were designed on the basis of the identified conserved regions #4 HTLVWH and #6 (F/Y)(I/Y)NDYN of xylanases from the glycosyl hydrolase family 10 aiming to provide novel sequences with xylanase activity.

SEQ ID NO 29 to 33 show the sequences obtained from a cow rumen sample.

6. PCR primers were designed on the basis of the identified conserved regions #5 WDVVNE and #6 (F/Y)(I/Y)NDYN of xylanases from the glycosyl hydrolase family 10 aiming to provide novel

sequences with xylanase activity.

SEQ ID NO 34 to 36 show the sequences obtained from a soil sample. SEQ ID NO 37 to 45 show the sequences obtained from a cow rumen sample

7. PCR primers were designed on the basis of the identified conserved regions #8 DGGTYDIY and #9 EGYQSSG of xylanases from the glycosyl hydrolase family 11 aiming to provide novel sequences with xylanase activity.

SEQ ID NO 46 to 49 show the sequences obtained from a soil sample. SEQ ID NO 50 to 54 show the sequences obtained from a cow rumen sample.

60 clones with inserts were sequenced and resulted in 43 different sequences all encoding either a part of a cellulase or a part of a xylanase. Only 2 of the 43 sequences were similar to sequence found in the sequence databases Genbank. SEQ ID NO 49 was found to be similar to Xylanase A from *Bacillus pumilus*. SEQ ID NO 42 was found to be similar to a xylanase from *Prevotella ruminicola*.

Example 3

Construction of novel hybrid DNA sequences encoding polypeptides with endoglucanase activity

Novel hybrid DNA sequences with endoglucanase activity were provided by first identifying two conserved regions common for the following family 45 cellulases (see WO 96/29397): *Humicola insolens* EGV (disclosed in WO 91/17243), *Fusarium oxysporum* EGV (Sheppard et al., Gene (1994), Vol. 15, pp.163-167), *Thielavia terrestris*, *Myceliophthora thermophila*, and *Acremonium* sp (disclosed in WO 96/29397).

The amino acid sequence alignment revealed two conserved region.

The first conserved region "Thr Arg Tyr Trp Asp Cys Cys Lys Pro/Thr" shown in SEQ ID NO 57 corresponds to position 6 to 14 of SEQ ID NO 55 showing the *Humicola insolens* EG V 43 KDa endoglucanase.

The second conserved region "Trp Arg Phe/Tyr Asp Trp Phe" shown in SEQ ID NO 58 corresponding to positions 169 to 198 of SEQ ID NO 55 showing the *Humicola insolens* EGV 43 KDa

endoglucanase.

Two degenerate, deoxyinosine-containing oligonucleotide primers (sense; primer s and antisense; primer as) were constructed) for PCR amplification of unknown gene sequences. The deoxyinosines are depicted by an I in the primer sequences.

Primers s and primer as are shown in SEQ ID No. 59 and 60 respectively.

The *Humicola insolens* EG V structural gene sequence (SEQ ID NO 55) was used as the known DNA sequence. A number of fungal DNA sequences mentioned below were used as the unknown sequences.

PCR cloning of the family 45 cellulase core region and the linker/CBD of *Humicola insolens* EG V.

Approximately 10 to 20 ng of double-stranded, cellulase-induced cDNA from *Humicola nigrescens*, *Cylindrocarpon* sp., *Fusarium anguioides*, *Gliocladium catenulatum*, and *Trichothecium roseum* prepared, as described above in the Material and Methods section were, PCR amplified in Expand buffer (Boehringer Mannheim, Germany) containing 200 µM each dNTP and 200 pmol of each degenerate Primer s (SEQ ID NO 59) and Primer as (SEQ ID NO 60) a DNA thermal cycler (Perkin-Elmer, Cetus, USA) and 2.6 units of Expand High Fidelity polymerase (Boehringer Mannheim, Germany). 30 cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 min, annealing at 55°C for 2 min, and extension at 72°C for 3 min, followed by extension at 72°C for 5 min.

The PCR fragment coding for the linker/CBD of *H. insolens* EGV was generated in Expand buffer (Boehringer Mannheim, Germany) containing 200 µM each dNTP using 100 ng of the pCaHj418 template, 200 pmol forward primer 1 (SEQ ID NO 61), 200 pmol reverse primer 1 (SEQ ID NO 62). 30 cycles of PCR were performed as above.

Construction of hybrid genes using splicing by overlap extension (SOE)

The PCR products were electrophoresed in 0.7 % agarose gels (SeaKem, FMC), the fragments of interest were excised from the

gel and recovered by Qiagen gel extraction kit (Qiagen, USA) according to the manufacturer's instructions. The recombinant hybrid genes were generated by combining the overlapping PCR fragments from above (ca. 50 ng of each template) in Expand buffer (Boehringer Mannheim, Germany) containing 200 µM each dNTP in the SOE reaction. Two cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 min, annealing at 50 C for 2 min, and extension at 72°C for 3 min, the reaction was stopped, 250 pmol of each end-primer: forward primer 2 (SEQ ID NO 63) encoding the TAKA-amylase signal sequence from *A. oryzae*, reverse primer 2 (SEQ ID NO 64) was added to the reaction mixture, and an additional 30 cycles of PCR were performed using a cycle profile of denaturation at 94°C for 1 min, annealing at 55 °C for 2 min, and extension at 72°C for 3 min.

Construction of the expression cassettes and heterologous expression in *Aspergillus oryzae*

The PCR-generated, recombinant fragments were electrophoresed in 0.7 % agarose gels (SeaKem, FMC), the fragments were excised from the gel and recovered by Qiagen gel extraction kit (Qiagen, USA) according to the manufacturer's instructions. The DNA fragments were digested to completion with BamHI and XbaI, and ligated into BamHI/XbaI-cleaved pHD414 vector. Co-transformation of *A. oryzae* was carried out as described in Christensen et al. (1988), Bio/Technology 6, 1419-1422. The AmdS+ transformants were screened for cellulase activity using 0.1 % AZCl-HE-cellulose in a plate assay as described above. The cellulase-producing transformants were purified twice through conidial spores, cultivated in 250 ml shake flasks, and the amount of secreted cellulase was estimated by SDS-PAGE, Western blot analysis and the activity assay as described earlier (Kauppinen et al. (1995), J. Biol. Chem. 270, 27172-27178;; Kofod et al. (1994), J. Biol. Chem. 269, 29182-29189; Christgau et. al,(1994), Biochem. Mol. Biol. Int. 33, 917 - 925).

Nucleotide sequence analysis

The nucleotide sequences of the novel hybrid gene fusions were determined from both strands by the dideoxy chain-termination method (Sanger et al., (1977), Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467), using 500 ng template, the Taq deoxy-terminal cycle sequencing kit (Perkin-Elmer, USA), fluorescent labeled terminators and 5 pmol of synthetic oligonucleotide primers. Analysis of the sequence data was performed according to Devereux et al., 1984 (Devereux et al., (1984), Nucleic Acids Res. 12, 387-395).

The provided novel hybrid DNS sequences an the deduced protein sequences are shown in SEQ ID NO 65 to 74.

SEQ ID NO 65 shows the hybrid gene construct comprising the family 45 cellulase core region from *Humicola nigrescens* and the linker/CBD of *Humicola insolens* EG V. SEQ. ID No 66 shows the deduced amino acid sequence of the hybrid gene construct.

SEQ ID NO 67 shows the hybrid gene construct comprising the family 45 cellulase core region from *Cylindrocarpon* sp. and the linker/CBD of *Humicola insolens* EG V. SEQ ID NO 68 shown the deduced amino acid sequence of the hybrid gene construct.

SEQ ID NO shows the hybrid gene construct comprising the family 45 cellulase core region from *Fusarium anguioides* and the linker/CBD of *Humicola insolens* EG V. SEQ ID NO 70 shows the deduced amino acid sequence of the hybrid gene construct.

SEQ ID NO 71 shows the hybrid gene construct comprising the family 45 cellulase core region from *Gliocladium catenulatum* and the linker/CBD of *Humicola insolens* EG V. SEQ ID NO 72 shows the deduced amino acid sequence of the hybrid gene construct.

SEQ ID NO 73 shows the novel gene construct comprising the family 45 cellulase core region from *Trichothecium roseum* and the linker/CBD of *Humicola insolens* EG V. SEQ ID NO 74 shows the deduced amino acid sequence of the hybrid gene construct.

SEQUENCE LISTING

(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Novo Nordisk A/S
(B) STREET: Novo Alle
(C) CITY: Bagsvaerd
(E) COUNTRY: Denmark
(F) POSTAL CODE (ZIP): DK-2880
(G) TELEPHONE: +45 4444 8888
(H) TELEFAX: +45 4449 3256
(ii) TITLE OF INVENTION: Method for providing novel DNA sequences
(iii) NUMBER OF SEQUENCES: 74
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 747 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(vi) ORIGINAL SOURCE:
(B) STRAIN: Bacillus sp. AC13, NCIMB No. 40482
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..747
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
ATG AGA CAA AAG AAA TTG ACG TTC ATT TTA GCC TTT TTA GTT TGT TTT          48
Met Arg Gln Lys Lys Leu Thr Phe Ile Leu Ala Phe Leu Val Cys Phe
 1               5                  10                  15

GCA CTA ACC TTA CCT GCA GAA ATA ATT CAG GCA CAA ATC GTC ACC GAC          96
Ala Leu Thr Leu Pro Ala Glu Ile Ile Gln Ala Gln Ile Val Thr Asp
            20                  25                  30

AAT TCC ATT GGC AAC CAC GAT GGC TAT GAT TAT GAA TTT TGG AAA GAT         144
Asn Ser Ile Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp
        35                  40                  45

AGC GGT GGC TCT GGG ACA ATG ATT CTC AAT CAT GGC GGT ACG TTC AGT         192
Ser Gly Gly Ser Gly Thr Met Ile Leu Asn His Gly Gly Thr Phe Ser
    50                  55                  60

GCC CAA TGG AAC AAT GTT AAC AAC ATA TTA TTC CGT AAA GGT AAA AAA         240
Ala Gln Trp Asn Asn Val Asn Asn Ile Leu Phe Arg Lys Gly Lys Lys
65                  70                  75                  80

TTC AAT GAA ACA CAA ACA CAC CAA CAA GTT GGT AAC ATG TCC ATA AAC         288
Phe Asn Glu Thr Gln Thr His Gln Gln Val Gly Asn Met Ser Ile Asn
                85                  90                  95

TAT GGC GCA AAC TTC CAG CCA AAC GGA AAT GCG TAT TTA TGC GTC TAT         336
Tyr Gly Ala Asn Phe Gln Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr
            100                 105                 110

GGT TGG ACT GTT GAC CCT CTT GTC GAA TAT TAT ATT GTC GAT AGT TGG         384
Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr Ile Val Asp Ser Trp
        115                 120                 125

GGC AAC TGG CGT CCA CCA GGG GCA ACG CCT AAG GGA ACC ATC ACT GTT         432
Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr Ile Thr Val
    130                 135                 140
```

```
GAT GGA GGA ACA TAT GAT ATC TAT GAA ACT CTT AGA GTC AAT CAG CCC      480
Asp Gly Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro
145                 150                 155                 160

TCC ATT AAG GGG ATT GCC ACA TTT AAA CAA TAT TGG AGT GTC CGA AGA      528
Ser Ile Lys Gly Ile Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Arg
                165                 170                 175

TCG AAA CGC ACG AGT GGC ACA ATT TCT GTC AGC AAC CAC TTT AGA GCG      576
Ser Lys Arg Thr Ser Gly Thr Ile Ser Val Ser Asn His Phe Arg Ala
            180                 185                 190

TGG GAA AAC TTA GGG ATG AAC ATG GGG AAA ATG TAT GAA GTC GCG CTT      624
Trp Glu Asn Leu Gly Met Asn Met Gly Lys Met Tyr Glu Val Ala Leu
        195                 200                 205

ACT GTA GAA GGC TAT CAA AGT AGC GGA AGT GCT AAT GTA TAT AGC AAT      672
Thr Val Glu Gly Tyr Gln Ser Ser Gly Ser Ala Asn Val Tyr Ser Asn
    210                 215                 220

ACA CTA AGA ATT AAC GGT AAC CCT CTC TCA ACT ATT AGT AAT GAC AAG      720
Thr Leu Arg Ile Asn Gly Asn Pro Leu Ser Thr Ile Ser Asn Asp Lys
225                 230                 235                 240

AGC ATA ACT CTA GAT AAA AAC AAT TAA                                  747
Ser Ile Thr Leu Asp Lys Asn Asn  *
                245
```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 249 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Met Arg Gln Lys Lys Leu Thr Phe Ile Leu Ala Phe Leu Val Cys Phe
 1               5                  10                  15

Ala Leu Thr Leu Pro Ala Glu Ile Ile Gln Ala Gln Ile Val Thr Asp
            20                  25                  30

Asn Ser Ile Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp
        35                  40                  45

Ser Gly Gly Ser Gly Thr Met Ile Leu Asn His Gly Gly Thr Phe Ser
    50                  55                  60

Ala Gln Trp Asn Asn Val Asn Asn Ile Leu Phe Arg Lys Gly Lys Lys
65                  70                  75                  80

Phe Asn Glu Thr Gln Thr His Gln Gln Val Gly Asn Met Ser Ile Asn
                85                  90                  95

Tyr Gly Ala Asn Phe Gln Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr
            100                 105                 110

Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr Ile Val Asp Ser Trp
        115                 120                 125

Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr Ile Thr Val
    130                 135                 140

Asp Gly Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro
145                 150                 155                 160

Ser Ile Lys Gly Ile Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Arg
                165                 170                 175
```

Ser Lys Arg Thr Ser Gly Thr Ile Ser Val Ser Asn His Phe Arg Ala
180 185 190

Trp Glu Asn Leu Gly Met Asn Met Gly Lys Met Tyr Glu Val Ala Leu
195 200 205

Thr Val Glu Gly Tyr Gln Ser Ser Gly Ser Ala Asn Val Tyr Ser Asn
210 215 220

Thr Leu Arg Ile Asn Gly Asn Pro Leu Ser Thr Ile Ser Asn Asp Lys
225 230 235 240

Ser Ile Thr Leu Asp Lys Asn Asn *
245

(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Conserved region"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Asp Gly Gly Thr Tyr Asp Ile Tyr
1 5

(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Conserved region"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Glu Gly Tyr Gln Ser Ser Gly
1 5

(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer e"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCGAATTCAT GAGACAAAAG AAATTGACG 29

(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer arc "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AACAGTGATG GTTCCCTTAG GC 22

(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer f "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CTAGAGTCGA CTTAATTGTT TTTATCTAGA G 31

(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer d_{rc} "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AACAGTGATG GTTCCCTTAG GC 22

(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer ab "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GCCTAAGGGA ACCATCACTG TTGAYGGXGG XACXTAYGAY AT 42

(Y=C or T, X= 25% A and 75% Inosin)

(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer cd "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

AATGCTATAT ACATTAGCAC TTCCXSWXSW YTGGTAXCCY TC 42

(S=G or C, W=A or T, Y=C or T, X= 25% A and 75% Inosin)

(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 747 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: hybrid DNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..747
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

```
ATG AGA CAA AAG AAA TTG ACG TTC ATT TTA GCC TTT TTA GTT TGT TTT          48
Met Arg Gln Lys Lys Leu Thr Phe Ile Leu Ala Phe Leu Val Cys Phe
 1               5                  10                  15

GCA CTA ACC TTA CCT GCA GAA ATA ATT CAG GCA CAA ATC GTC ACC GAC          96
Ala Leu Thr Leu Pro Ala Glu Ile Ile Gln Ala Gln Ile Val Thr Asp
            20                  25                  30

AAT TCC ATT GGC AAC CAC GAT GGC TAT GAT TAT GAA TTT TGG AAA GAT         144
Asn Ser Ile Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp
        35                  40                  45

AGC GGT GGC TCT GGG ACA ATG ATT CTC AAT CAT GGC GGT ACG TTC AGT         192
Ser Gly Gly Ser Gly Thr Met Ile Leu Asn His Gly Gly Thr Phe Ser
    50                  55                  60

GCC CAA TGG AAC AAT GTT AAC AAC ATA TTA TTC CGT AAA GGT AAA AAA         240
Ala Gln Trp Asn Asn Val Asn Asn Ile Leu Phe Arg Lys Gly Lys Lys
65                  70                  75                  80

TTC AAT GAA ACA CAA ACA CAC CAA CAA GTT GGT AAC ATG TCC ATA AAC         288
Phe Asn Glu Thr Gln Thr His Gln Gln Val Gly Asn Met Ser Ile Asn
                85                  90                  95

TAT GGC GCA AAC TTC CAG CCA AAC GGA AAT GCG TAT TTA TGC GTC TAT         336
Tyr Gly Ala Asn Phe Gln Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr
            100                 105                 110

GGT TGG ACT GTT GAC CCT CTT GTC GAA TAT TAT ATT GTC GAT AGT TGG         384
Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr Ile Val Asp Ser Trp
        115                 120                 125

GGC AAC TGG CGT CCA CCA GGG GCA ACG CCT AAG GGA ACC ATC ACT GTT         432
Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr Ile Thr Val
    130                 135                 140

GAC GGG GGG ACG TAT GAT ATC TAC AAG CAC CAA CAG GTC AAT CAG CCA         480
Asp Gly Gly Thr Tyr Asp Ile Tyr Lys His Gln Gln Val Asn Gln Pro
145                 150                 155                 160

TCT ATT CAG GGC ACC GCC ACC TTC AAT CAG TAC TGG TCG ATT CGA CAG         528
Ser Ile Gln Gly Thr Ala Thr Phe Asn Gln Tyr Trp Ser Ile Arg Gln
                165                 170                 175

AGC AAG CGG ACC AGC GGC ACT GTC ACT ACG GCA AAC CAC TTT AAT GCC         576
Ser Lys Arg Thr Ser Gly Thr Val Thr Thr Ala Asn His Phe Asn Ala
            180                 185                 190

TGG GCT GCT CTT GGC ATG AAT ATG GGT GCA TTC AAT TAC CAG ATC CTC         624
Trp Ala Ala Leu Gly Met Asn Met Gly Ala Phe Asn Tyr Gln Ile Leu
        195                 200                 205

GTT ACT GAG GGC TAC CAA TCT ACC GGA AGT GCT AAT GTA TAT AGC AAT         672
Val Thr Glu Gly Tyr Gln Ser Thr Gly Ser Ala Asn Val Tyr Ser Asn
    210                 215                 220

ACA CTA AGA ATT AAC GGT AAC CCT CTC TCA ACT ATT AGT AAT GAC AAG         720
Thr Leu Arg Ile Asn Gly Asn Pro Leu Ser Thr Ile Ser Asn Asp Lys
225                 230                 235                 240

AGC ATA ACT CTA GAT AAA AAC AAT TAA                                     747
Ser Ile Thr Leu Asp Lys Asn Asn  *
                245
```

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 249 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

```
Met Arg Gln Lys Lys Leu Thr Phe Ile Leu Ala Phe Leu Val Cys Phe
 1               5                  10                  15

Ala Leu Thr Leu Pro Ala Glu Ile Ile Gln Ala Gln Ile Val Thr Asp
            20                  25                  30

Asn Ser Ile Gly Asn His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp
        35                  40                  45

Ser Gly Gly Ser Gly Thr Met Ile Leu Asn His Gly Gly Thr Phe Ser
    50                  55                  60

Ala Gln Trp Asn Asn Val Asn Asn Ile Leu Phe Arg Lys Gly Lys Lys
65                  70                  75                  80

Phe Asn Glu Thr Gln Thr His Gln Gln Val Gly Asn Met Ser Ile Asn
                85                  90                  95

Tyr Gly Ala Asn Phe Gln Pro Asn Gly Asn Ala Tyr Leu Cys Val Tyr
            100                 105                 110

Gly Trp Thr Val Asp Pro Leu Val Glu Tyr Tyr Ile Val Asp Ser Trp
        115                 120                 125

Gly Asn Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr Ile Thr Val
    130                 135                 140

Asp Gly Gly Thr Tyr Asp Ile Tyr Lys His Gln Gln Val Asn Gln Pro
145                 150                 155                 160

Ser Ile Gln Gly Thr Ala Thr Phe Asn Gln Tyr Trp Ser Ile Arg Gln
                165                 170                 175

Ser Lys Arg Thr Ser Gly Thr Val Thr Thr Ala Asn His Phe Asn Ala
            180                 185                 190

Trp Ala Ala Leu Gly Met Asn Met Gly Ala Phe Asn Tyr Gln Ile Leu
        195                 200                 205

Val Thr Glu Gly Tyr Gln Ser Thr Gly Ser Ala Asn Val Tyr Ser Asn
    210                 215                 220

Thr Leu Arg Ile Asn Gly Asn Pro Leu Ser Thr Ile Ser Asn Asp Lys
225                 230                 235                 240

Ser Ile Thr Leu Asp Lys Asn Asn  *
                245
```

(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 409 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS1/9
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

```
GAATTCGGCT TGGGTGGAAT CTGGGGAACA CGTTGGATGC TACCGGAGAC TGGATCAAAG  60
GGCCGTCCGT GAGCGCCTAC GAGACCGCCT GGGGCAATCC CGTCACCACC AAGGCTATGT  120
TCGACGGCAT CAAAGCGTCC GGCTTCAACT TTGTTCGCAT TCCCGTGGCG TGGTCCAACA  180
TGATGGGCCC GGACTATACC ATTAACCCGG CGTTGATGGC GAGAGTCGAG AAGTGGTGAA  240
TTACGGTCTG GCCGACAACA TGTATGTCAT GATCAACATC CACTGGGACG CGGCTGGATC  300
ACTAAATTCC CACCAACTAC GACGAAAGCA TGAAGAAGTA TAAGGCGGTC TGGAGCCAGA  360
```

TCGCCGACCA TTTCAAAGCT ACTCCGACCA CCTCATCTTC GAAAAGCCG 409

(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 408 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS1/12
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AATTCGGCTT GGGTGGAATC TGGGGAACAC TCTGGAAGCC TGCGGCGGGA TCAAATGCAG 60
TTCCGTGCGC GATTTCGAGA CGGCTTGGGG CAACCCCGTC ACGACCAAGG CCATGATCGA 120
CGGCGTCAAG GCGGCCGGCT TCAGGTCCAT ACGCATCCCC GTCGCCTGGT CGAACCTGAT 180
GGGACCTAAG CCCGACTACA CTATCAATAA GAAGCTGATG GCACGAGTCG AGCAGGTCGC 240
CCGGTACGGC CTCGACAACG ACATGTACGT CATCATCAAC ATTCACTGGG ACGCGGCTGG 300
ATCCACCGCT TCTCCACCGA CTACAACGAA ATGCATGARG AATTACAAGG CGGTGTGGGG 360
CCAGGTAGCC GACCATTTCA AGGGCTACTC CGACCACCTC ATCTTCGA 408

(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 416 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KN1/9
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

AATTCGGCTT CTCGAAGATG AGGTGGTCGG AGTAGCCTTT GAAATGGTCG GCGATCTGGC 60
TCCAGACCGC CTTATACTTC TTCATGCTTT CGTCGTAGTT GGTGGGGAAT TTAGTGATCC 120
AGCCGCCGTC CCAGTGGATG TTGATCATGA CATACATGTT GTCGGCCAGA CCGTAATTCA 180
CCACTTCCTC GACTCTCGCC ATCAACGCCG GGTTAATGGT ATAGTCCGGG CCCATCATGT 240
TGGACCACGC CACGGGAATG CGAACAAAGT TGAAGCCGGA CGCTTTGATG CCGTCGAACA 300
TAGCCTTGGT GGTGACGGGA TTGCCCCAGG CGGTCTCGTA GGCGCTCACG GACGGCCCTT 360
GATCCAGTC TCCGGTAGCA TCCAACGTGT TCCCCARATT CCACCCAAGC CGAATT 416

(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 490 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM1/2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

AATTCGGCTT GTTCCGCAAG CGTCAAAGGG GATGTGATGT ACCAGATCAA GGCAAAGCTC 60
GGTCTGAAAT AAAACTAGTC AAAACTAGCC AAAACTAGTC AGGCTAGTCA GAACCAGTTA 120
GCACAATCGT AAAAACTAAA AGTATGAGCG ACGGCAATTT CAACCGCGCC CTCCTGCCGA 180
AGAACGAACT CTCTGCAGGA CTCAGGGCTG GCAAAGCACA GATGCGCACC AAGGCTGAAA 240
CAGGCGTTGG AGACTGTACT CGACNAATAC TTCCCCTCTG CCGACATGTC GCTCCGAAAC 300
GCAATCCACG AACGATCCTC CAACTCTTAC AACAGTAGGA CAAAGGTGAA ACGTATTTAA 360
TTATGCTTCC TGAATTNTCA TTAACACNAT GCCTGTGTGG CACCCATCCG CGTNTTCAAT 420
GGTGTTCACC AGGGCATCCT TTACTCATCC CACAGGTTAA GCAANTGGCC AAANAACACC 480
GTCCGGCTTC 490

(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 492 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KN2/2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

AATTCGGCTT GTTGTTGCCG CCGGTGGTGC GGACCACGTC AATAAAAGTC TGGTTGTAAG 60
AATTCTGCAC AGCCAGATTC TCAGGCTCGG GCTTGCCCCA GTTATCGCGC AGGTGAACCT 120
CGTTAGTACC AGCAAAGGCT ACGCGGTAGT CGTAGTTGGC AAACTCGCTG GCGATATTCA 180
GCCACAGCAG GGCGAGTTTC TGGTTGTTCT CGTCCTTGTA CTGATAGGTA GGACRACCCT 240
CCAGCCACTT GTCGTGATGC GTATTGATGA TGACTTTTAG GTCATTCTCG AAGCACCARC 300
CCACAACCTC TTTGATACGT GCCAGCCAAG CCTTGTCAAT GCTCATGGCA ACGGGATTGG 360
TGATGTTGCA CTGCCACCGG AMSGGAATGC GGATGGCGTT RAAAC:TGCA TCCTTGACTG 420
CCTTGATAAC TTTTTTGTTA CAACGGGATT GCCCCATGCC GTCTCACCCT TAATACTGTT 480
CTCATACATC CG 492

(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 574 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM2/5
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

AATTCGGCTT GTTGTTGCCG CCGGTGGTAC GGATGGTGTT CACCACCAAC TGGTTCCACT 60
CGTTGAGGGT TTTATACTGC TTACCGCCAT CGGTACGGTT TGCGCCCCAT CCCCAGCCGC 120
CGTCCTGAAT CTCGTTGAAC GACTCGAATA TGAGGAATTC GCCCTTGTCC TTGAAGGCTT 180
CGGCAATCTG TTTCCANGTT TTCTCAATAC GGTTCTTGAT GTTGCTGTTG GTCGTTGAAT 240
TGTTGGCAGC GCCCTTAATG TCAACCAGTA CTCATCGTGA TGCATGTTCA GGATNACNTT 300
CAGTCCGGCA CTTCGGCCCA CTCCACATTC TGCCTGACTT CTGCTATGTA TTTAGCATCT 360
ATCCCCATTC CAAATGTTTC TGGTANTTGC CCATGTTACC CGANACTTAN GTGCTGGCAC 420
AACGTTTTTA NGTTTGTTAA AAACCGCAAA GGCTTGGCAT TTCCAATATC CCANTGGGGA 480
ACCNAACNTC NCACCCNGCC GGTACAAATG GTNCCCCNTT TCCCCCAACC CAAATCCNCC 540
NCNGGGGGCC GTTACNATTG NATCNAACCG GTAC 574

(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 520 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM2/6
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AATTCGGCTT GTTGTTGCCG CCGGTGGTTC TCACGGTGGT GACGAAGCTC TGAGCATANC 60
TGTTGATGGC GTTGTAGGCC GATGTGGCTA TGGCTTCGTT GTACCTGCCG GTAGCGGCAA 120
AGGATGCGAA ACACCAGGAG CTCAAGGGAT CCAGCATCTC GTTGAAGCTC TCGAAGAGCA 180
AGCGCTGTCC GCAGTCCCGG AATTCCTGTG CTATCTGCTG CCACAGACGT TCATANCGGG 240
AGCGGTTCAN CGCGTATTTG TCCTCGGANG CCTTGATCCA CNACTTGAAA CNANTTGCTG 300
TCTGCGCCCG TGTCGTGGTG AACGTTGAAT NATGCAGTAC AAGCCCTGGT CTAGGANACT 360
ATCACCACTT CATGCACGCG GGCCATCCAC GCCNCATCCA CNTTGCCGGC GCTGTCCATN 420
TTGTTATACC ACTTCATGGC CCACGGATGG CACCAAACCC GGATCTTTNT CNTCCTGAAN 480
AACAANGGGT GGTGGGATAT TAACCCAACA GGTCCGAAGA 520

(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 194 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM3/2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

AATTCGGCTT GAGCACCTGA TTTTTGAGGG CTACAACGAG ATGCTCGACA AGTATGACTC 60
CTGGTGTTTT GCCACCTTCG GACGCTCGGC AGGCTATAAC GCTACAGACG CCGCCGATGC 120
CTATAAAGCC ATCAACAACT ATGCCCAGAG CTTCGTCAAC GCCGTACGCA CCACCGGCGG 180

CAACAACAAG CCG 194

(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 160 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM3/8
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

AATTCGGCTT GAGCACTTGA TTTTCGAGGC CTACAACGAG ATGCTCGATG CCCAGAGCTC 60
GTGGAACTTT GCCCAGACCA GCACAGCCTA TGATGCTATC AACAACTATG CCCAAAGCTT 120
CGTCAACATT GTTCGTACCA GCGGCGGCAA CAACAAGCCG 160

(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 193 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM3/9
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

AATTCGGCTT GAGCATTTGA TCTTCGAGAG TTACAACGAG ATGCTCGATA CGGAAGATTC 60
CTGGTGCTTC GCCTCGTTTG CAGCGCAGGG CAGTTACAAT GCCACCATCG CGCGTTCGGC 120
CTACAACGGC ATTAATAGCT ATGCGCAGAC TTTCGTCAAC ACCGTACGTA CCACCGGCGG 180
CAACAACAAG CCG 193

(2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 166 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

AATTCGGCTT CAYACGCTGG TGTGGCACTC TCAGATCGGT CGTTGGATGA CTGCCGAGGG 60
TACAACCAAG GAGCAGTTCT ATGCTCGTAT GAAGAACCAT ATCCAGGCTA TCGTTACTCG 120
TTACAAGGAT GTGGTGTACT GCTGGGACGT CGTCAACGAG AAGCCG 166

(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 178 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AATTCGGCTT CTCGTTAACG ACGTCCCAGG CATCGATCTT ACCGCAGAAA TGGCCGGCTA 60
CCGTCTCTAT GTAACTGCGC ATGGTCTCAA CCATCTCATC GTGGCTCTTG GGAGTGCCGT 120
CAGCGTGGTT GAAAAAGAAA TCGGGAGTCT GATTGTGCCA CACCAGCGTA TGAAGCCG 178

(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 181 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/4
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

AATTCGGCTT CAYACGCTGG TGTGGCACTC GCAGGCACCC GACTGGTGGT TTACCAACGG 60
CTATGCTGCC AGCCCTGTCT CAAAGGAAGT GCTGAAAGAG CGGCTCATCA AGCATATTAA 120
GACCGTTGTT GGCCATTTCA AGGGCCAAGT CTTTGGCTGG GACGTCGTCA ACGARAAGCC 180
G 181

(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 199 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/7
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

AATTCGGCTT CATACGTTGG TGTGGCACAA TCAGACGCCG GCCTGGTTCT TCCGCAGGGG 60
CTACAACGAG AACCTGCCTC TGGCGGACCG CGAGACCATG CTGGCGAGGC TGGAGAGCTA 120
TATCCGCGGT GTGCTGACCT ATGTGCAGGA GAATTATCCC GGGATCGTCT ACGCCTGGGA 180
CGTCGTCAAC GAGAAGCCG 199

(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 185 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/8
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

AATTCGGCTT GGCACGGACA GACGCCGCAG TGGTTCTTCT ACGAGAACTA TAATACTTCA 60
GGAAAACTTG CAAGCAGGGA AACGATGCTG GCAAGAATGG GAAACTATAT TAANGGCGTG 120
CTTGGCTTCG TGCAGGACAA TTATCCCGGC GTCATCTATG CGTGGGACGT TGTCAACGAG 180
AACCG 185

(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 208 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM4/9
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

ATCTGCAGAA ATTCGGCTTC TCGTTAACGA CGTCCCATGC ATAGATGACA CCCGGATATT 60
CACTCTGGAT AAAACCAAGC ACACCCTTTA TATAATTTTC AAGTCTGGCA AGCATGGTCT 120
CTCTGTCGGT ATAGGGAAAT GACTCGTTAT AGTGCTCACA GAAAAACCAC TTCGGTGTCT 180
GATTGTGCCA CACCAGCGTA TGAAGCCG 208

(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 310 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM5/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

AATTCGGCTT GTTGTAGTCG TTGTAGTACA GCTTGCAGTT TGAAGGAGCG TACTTTCTTG 60
CATATGTGAA CGCTTTCTCA ATAAATGCGT TGCTGCCGTA AACCTGTACC CAAGGGANAA 120
GCGCCGTTGC CGTACCCGGA ACTCTTGCTC CGCCGTTGTT ACGTGTTCTG TTGGAGTCAC 180
ANAAAATACA CTCGTTGCAG ACATCTAAAG CTTAAAGGTT AATCCGGGAT ACTGTGACTG 240
ATAGGCCGAA CATATCTTGA AGTTACCTTC CAGTCCNGGT CCATACGGAA TGCTACCAGC 300
TTCGCCGTCC 310

(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 384 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM5/2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

AATTCGGCTT GTTGTANTNG TTGWWGAAGA NGTGGCAGNT TGCCGGTGCC GCATCATGGG 60
CATATTCAAA TGCCTTTGCA ATGAAGCTGT TGTCACCGTA AACCTGCACC CACGGGGACT 120
TGCCGTCATT GTAACCCGGC TCACGGGCGC CGCCTGCACC ACGCGTACGC GCATCGCTGT 180
CGGAGATACA CTCGTTGCAG ACGTCGTARG CGTANARGTT CAGCGTCNGA TAGTTGTTCT 240
TGTACATTGC AAMCATATTG TCAATGTANC YCTTGANGCG CTGGTTCATG ACAGTGGANT 300
TCACCCACTG ACCGCCGTCC TGGAAAGTTA TCCTTGAAAN AACCAGANCG GARTCTGGRA 360
GTGCCACNCC ANCGTRTGAA GCCG 384

(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 354 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM5/4
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

AATTCGGCTT CATACGTTGG TGTGGCACAA TCAGACGCCC GTATGGTTTT TTAAGGAAAA 60
CTGGGAAAAT GACTGGAACG CGCCTGCCGC CCCCAAAGAA ATCCTGCTCG CCCGCCTGGA 120
AAACTATATC CGGGATGTCA TGCGGCATGT GAATACCTGT TTCCCCGGTG TGGTCTACAC 180
CTGGGATGTG GTGAACGAAG CCATCGAACC GGGGCAGGGC GGTCCCGGCC TGTTCCGGAA 240
CCGCAATCCC TGGTTTGCTT TCACAGGCCA NGATTTCCTG CCGGCTGCCT TCCGGGCCCC 300
CGCGAAAACN AAGTCCCGGG ACAGAACCTG TGCTACAACG ACTACAACAA GCCG 354

(2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 374 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM5/5
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

AATTCGGCTT CATACGCTGG TGTGGCACAG CCAGACTCCT GACTGGTTCT TCAAGGAGAA 60
CTTCAGCTCA AACGGTCAGC TCGTATCAAA GGATATAATG AATCAGCGTA TCGAAAACTA 120
CATCAAGAAC GTATTCACAA TGCTCAATGC AGAGTATCCT ACAGTTCAGT TCTATGCTTA 180
CGATGTAGCT AACGAGTGTA TGGCTGACAG CAGAAACGGC GGTCTCAGAC CGGCTGGCAT 240
GAATCAGCAG AACGGCGAAT CCCCATGGAA TCTTATCTAC GGCGACAACA GCTACCTCGA 300
TGTANCATTC AAGGCTGCTA AGAAATTATG CTCCTGCTGG CTGCNAACTT TTCTTCAACG 360
ACTACAACAA GCCG 374

(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 376 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM5/6
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

AATTCGGCTT CATACGCTGG TGTGGCACAG CCAGACTCCC GAGTGGTTCT TCAAGGAGGA 60
CTTCGACGAG AAGAAGGATT ACGTTTCTCC CGAAAAGATG AAGAAGCGTA TGGAGAACTA 120
CATCAAGAGC TTCTTCACAA CACTTACAGA GCTCTATCCC GACGTTGACT TCTATGCCTG 180
CGACGTTGTA AACGANGCAT GGACAGACGA CGGAAAGCCC CGTGAGGCAG GTCACTGTTC 240
ACAGTCCAAC AACTACGGCG CTTCCGACTG GGTTGCTGTA TTCGGCGACA ACTCATTCAT 300
CGACTACGCT TTCGAGTATG CAAGAAAGTA TGCTCCCGAN GGCTGCAAGC TCTACTACAA 360
CGACTACAAC AAGCCG 376

(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 166 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS6/3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

AATTCGGCTT TGGGATGTGG TGAACGAGGC CTTCAACGAA GACGGTTCAC GGCGCAGCGA 60
CGTTTTCCAG AATGTGCTCG GCAACGGCTA TATCGAGCAG GCATTCAGGA CCGCGCGTGC 120
GGCTGACCCC AATGCCAAAC TGTGCTACAA CGACTACAAC AAGCCG 166

(2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 151 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS6/5
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

AATTCGGCTT GTTGTAGTCG TTGTTGAACA GGCGGGTGGT TGGGTCTACC TCATGAGCAA 60
GTTGATACCA GTGCACAACA GCATCGAGGC CGCCGAGGGC ATCATAAACC TCGTGGTTAT 120
CTACCGGCTC GTTCACCACA TCCCAAAGCC G 151

(2) INFORMATION FOR SEQ ID NO: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 166 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS6/13
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

AATTCGGCTT GTTGTAGTCG TTGTAGCACA GTTTGGCATT GGGATCTGTA ACCCGTGCAG 60
CTTTGAATGC CTCTTCAATA TAGCTATTGC CAATCAGCCG TTGGAAGATT GAGGCACGCC 120
GTGAGCCATT GTCTTCGAAG GCCTCATTCA CCACATCCCA AAGCCG 166

(2) INFORMATION FOR SEQ ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 250 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS6A/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

AATTCGGCTT GTTGTAGTCG TTGWTGMAGA GTTTTACATC TTTTGGACCA TATTTGCGAG 60
CCAGACGACA GGCCTGACGG ACGTAGTCGA TATCACCCAG ATAGTCCTGC CAGTAGAAAT 120
TATCGCCGCC CACATCCCAT GTGGCATCTG GATTACCATT AGGATTATAC TTAGCAGAGT 180
GTTGTAATAA GTAGTTGCCT TGTCCGTCAT CACCACCACC AGAGATCGCC TCRTTCACCA 240
CATCCCAAAG 250

(2) INFORMATION FOR SEQ ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 247 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6A/4
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

AATTCGGCTT TGGGAYGTGG TGAAYGAGGC GATAGAGCTT AACGACAAGA CCGAAACCGG 60
ACTTCGTAAT TCATACTGGT ATCAAATAAT CGGTGACGAT TTCATATATT ACGCATTTCG 120
CTATGCATAT GACGCAAGAG AGGAACTGTG CGTTAAATAT GCGGCCGAGT ACGGCATTGA 180
CCCTTCGGAC AAAGAAGCGC TTAAAGCCAT CCGCCCCGCT TTCTGCAACA ACGACTACAA 240
CAAGCCG 247

(2) INFORMATION FOR SEQ ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 238 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6A/5
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

AATTCGGCTT TGGGATGTGG TGAACGAGGC TATCTCGGGT GGCGACAGTG ACGGCGACGG 60
TTACTACGAC CTCCAGCATT CCGAGGGCTA TAAGAACGGC ACTTGGGATG TAGGCGGCGA 120
TGCCTTCTAC TGGCAGGACT ACATGGGCGA CCTGGATTAC GTRCGTCAGG CTTGCCGACT 180
GGCCCGCAAA TACGGCCCTG AGGATGTGAA GCTYTKCATC AACGACTACA ACAAGCCG 238

(2) INFORMATION FOR SEQ ID NO: 40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 226 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6A/7
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

AATTCGGCTT GTTGTAGTCG TTGATGCACA ACAGGGCATT GGGGTCGGCC TCACGGGCAA 60
ACTCGAAAGC TTTGGCAATG AACTCGTCGC CGCAGAGTTT GTAATGACGA CTCTCACGAT 120
AGGGGCTGGG AGCCTGACCT GGACGGCGTC CGAAACCGCC AAAGCCACCA AAGCCACCAA 180
AGCCGCCACC GTCGGAAATG GCCTCGTTCA CTACATCCCA AAGCCG 226

(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 205 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6B/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

ATCTGCAGAA ATTCGGCTTT GGGACGTGGT GAACGAGGCT ATGGCCGACG ACGTTCGCCG 60
CTCGCCCTGG AACCCGAATC CGTCGCCTTA CCGCAACTCG AAACTCTATC AGTTGTGCGG 120
TGATGAGTTC ATCGCTAAAG CATTCCAATT CGCCCGTGAG GCCGACCCGA ACGCACAATT 180
GTGCATCAAC GACTACAACA AGCCG 205

(2) INFORMATION FOR SEQ ID NO: 42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 235 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6B/2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

AATTCGGCTT GTTGTAGTCG TTGATGAAGA GCTTCATATC CTGTGGACCA TACTTGCGAG 60
CCAGCTTAAC GGCAGTACGA ACATAGTCGA TATCGCCCAG ATAATCCTGC CAGAAGAAGC 120
TCTCGGTTGC AGCCTTTTCT GGATCTTCCT GATCCTTCAG GTGCTGCAAA GCATATACGC 180
CCTCAGCATC GGCATGTCCG CTTGAGAGTG CCTCGTTCAC CACATCCCAA AGCCG 235

(2) INFORMATION FOR SEQ ID NO: 43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6B/3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

AATTCGGCTT GTTGTAGTCG TTGATGAANA GTTTCAAGTC TTCCGGGTTG CCCTTGAAGT 60
GCTTGCGCGC ACTCTTAACC GCGGTACGCA CGTATTCGAN GTCGCCCATA TCGTCCTGCC 120
AAAAGAANAG CCATTCTGCA CTGAAGTCGG GTCGGTGTTG CGGCTACTGT TGTGCTGAAN 180
GGGATAATTG CCCTGCCCAT CGTTGCCGCC GCCAGANATA CCTCGTTCAC ACGTCCCAAA 240
GCCG 244

(2) INFORMATION FOR SEQ ID NO: 44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 212 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6B/4
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

AAATTCGGCT TGTTGTAGTC GTTGATGTAC AGGACCGGGG CTTTGCCGTA CTTGGCGCAA 60
GCCTCTGTTG CATAGGCGAA TGCAGCATCA ACCCAGTCTT TGGTGCTCGG GTAATAATTG 120
CCCCAGACAA AGTCGTTGGC AGATGCTCCC TGGGTGCGGA ATGCCCCGCC GGCACCGTCT 180
GCAAAGGTCT CGTTCACCAC GTCCCAAAGC CG 212

(2) INFORMATION FOR SEQ ID NO: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 190 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM6B/5
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

AATTCGGCTT GTTGTAGTCG TTGTAGAACA GACCTGCATT AGGATCAGCC TCGTGAGCAA 60
ACTGGAATGC CTTGAGGATG AACTCGTCAC CGCAGAGCTG ATAAGCGGTT GACTGACGGA 120
ATGACTGCTC GTAAGGAACA TCGGGGTTGT TGCCGTCGCT CATTGCCTCG TTTACCACGT 180
CCCAAAGCCG 190

(2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 234 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS8/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

AATTCGGCTT GACGGGGGGA CGTAYGAYAT CTACGAGACC ACCCGCTACA ACGAACCCTC 60
CATCATCGGC ACCGCCACCT TCAACCAGTA CTGGAGCGTG CGCCAGTCCA GGCGCACCGG 120

CGGCACCATC ACCACCGGCA ACCACTTCGA CGCCTGGGCC AGCCACGGCA TGAACCTGGG 180
CACCTTCAAC TACCAGATCC TGGCCACCGA RGGCTACCAA TSCTSCGGAA GCCG 234

(2) INFORMATION FOR SEQ ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 234 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS8/6
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

AATTCGGCTT GACGGGGGRA CGTACGACAT CTACGAGCAC CAGCAAGTCA ACCAGCCCTC 60
CATCCAAGGC ACTGCGACCT TCAACCAGTA CTGGTCCATC CGCCAGAGCA AGCGTTCCAG 120
CGGCACTGTG ACCACTGCCA ACCACTTCAA TGCTTGGGCC AAGTTGGGAA TGAACCTGGG 180
CAACTTCAAC TACCAGATTG TTTCCACTGA RGGCTACCAG WCCTSCGGAA GCCG 234

(2) INFORMATION FOR SEQ ID NO: 48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 234 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS8/11
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

AATTCGGCTT GACGGGGGGA CGTATGATAT CTACAAGCAC CAACAGGTCA ATCAGCCATC 60
TATTCAGGGC ACCGCCACCT TCAATCAGTA CTGGTCGATT CGACAGAGCA AGCGGACCAG 120
CGGCACTGTC ACTACGGCAA ACCACTTTAA TGCCTGGGCT GCTCTTGGCA TGAATATGGG 180
TGCATTCAAT TACCAGATCC TCGTTACTGA GGGCTACCAA TCTACCGGAA GCCG 234

(2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 213 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: NS8/12
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

AATTCGGCTT GACGGGGGGA CGTACGACAT TTATGAAACA ACCCGTGTCA ATCAGCCTTC 60
CATTATCGGG ATCGCAACCT TCAAGCAATA TTGGAGTGTA CGTCAAACGA AACGTACAAG 120
CGGAACGGTC TCCGTCAGTG CGCATTTTAG AAAATGGGAA AGCTTAGGGA TGCCAATGGG 180
GAAAATGTAT GAAACGGCAT TTACTGTAAG CCG 213

(2) INFORMATION FOR SEQ ID NO: 50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 196 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM8A/1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

AATTCGGCTT TGGGACGTGG TGAATGAGGC AATGGCAGAC AATGTTCGTC CTAACCCGTG 60
GAATCCCAAC CCCTCGCCCT ACCGTGACTC CCGCCACTAC AAATTGTGCG GCGACGAGTT 120
CATCGCCAAG GCATTCCAAT TCGCAAGGGA AGCCGACCCG AAGGCACAAT TGTTCAACAA 180
CGACTACAAC AAGCCG 196

(2) INFORMATION FOR SEQ ID NO: 51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 211 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM8A/3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

AATTCGGCTT GTTGTAGTCG TTGATGCACA GGACCGGGGC TTTGCCGTAC TTGGCGCAAG 60
CCTCTGTTGC ATAGGCGAAT GCAGCATCAA CCCAGTCTTT GGTGCTCGGG TAATAATTGC 120
CCCAAACAAA GTCGTTGGCA GATGCTCCCT GGGTGCGGAA TGCCCCGCCG GCACCGTCTG 180
CAAAGGTCTC GTTCACCACG TCCCAAAGCC G 211

(2) INFORMATION FOR SEQ ID NO: 52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 240 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM8B/7
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

AATTCGGCTT GACGGGGGGA CGTACGACAT CTACAAGACC ACCAGATACG AACAGCCCTC 60
TATCGACGGC ACACAGACCT TCGACCAGTA CTGGAGCGTA AGACAGTCCA AGCCACAGGG 120
CGAGGGCAAG AAGATAGAAG GTACTATCTC AGTGTCCAAG CACTTCGATG CGTGGAAAAA 180
GTGCGGCCTT GAGCTCGGAA ATATGTATGA AGTANCTCTT ACTATCGAAG GGCTAAGCCG 240

(2) INFORMATION FOR SEQ ID NO: 53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 229 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM8A/9
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

AATTCCCGGA GGTTTGGCAG CCTTCAATAG TAAGAGCAGC TTCATACATT AATCCTAATT 60
TCATTCCTTT GCTTGTCCAA GCTTTGAAGT GGTCACTTAC AGAAATAGTT CCACTAGTTT 120
TTTTTTCAGT TCTGACACTC CAGAATTGTT TAAATGTAGC AGTACCATCA ATTGAAGGTT 180
GATTAATTCT GTCAGTGGTA TANATATCAT ACGTCCCCCC ATCAAGCCG 229

(2) INFORMATION FOR SEQ ID NO: 54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 234 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Hybrid DNA
(vi) SCIENTIFIC NAME: KM8B/10
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

AATTCGGCTT GACGGGGGGA CGTACGACAT ATACGAGACT ACTCGTTACA ACCAGCCTTC 60
AATCGAAGGC AACACTACTT TCCAGCAGTA CTGGAGCGTT CGTACATCCA AGCGCACCAG 120
CGGTACCATT TCCGTATCCG AGCACTTTAA GGCTTGGGAA CGCATGGGTA TGAGATGCGG 180
AAACCTTTAT GAGACTGCTT TAACTGTTGA GGGCTACCAN ACCACCGGAA GCCG 234

(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1060 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Humicola insolens
(B) STRAIN: DSM 1800
(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 73..927
(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: 10..72
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 10..927
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

```
GGATCCAAG ATG CGT TCC TCC CCC CTC CTC CCG TCC GCC GTT GTG GCC                48
          Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala
          -21 -20                 -15                 -10

GCC CTG CCG GTG TTG GCC CTT GCC GCT GAT GGC AGG TCC ACC CGC TAC              96
Ala Leu Pro Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr
            -5                  1               5

TGG GAC TGC TGC AAG CCT TCG TGC GGC TGG GCC AAG AAG GCT CCC GTG              144
Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val
     10                  15                  20

AAC CAG CCT GTC TTT TCC TGC AAC GCC AAC TTC CAG CGT ATC ACG GAC              192
Asn Gln Pro Val Phe Ser Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp
 25                  30                  35                  40

TTC GAC GCC AAG TCC GGC TGC GAG CCG GGC GGT GTC GCC TAC TCG TGC              240
Phe Asp Ala Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys
                45                  50                  55

GCC GAC CAG ACC CCA TGG GCT GTG AAC GAC GAC TTC GCG CTC GGT TTT              288
Ala Asp Gln Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe
            60                  65                  70

GCT GCC ACC TCT ATT GCC GGC AGC AAT GAG GCG GGC TGG TGC TGC GCC              336
Ala Ala Thr Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala
        75                  80                  85

TGC TAC GAG CTC ACC TTC ACA TCC GGT CCT GTT GCT GGC AAG AAG ATG              384
Cys Tyr Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met
    90                  95                  100

GTC GTC CAG TCC ACC AGC ACT GGC GGT GAT CTT GGC AGC AAC CAC TTC              432
Val Val Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe
105                 110                 115                 120

GAT CTC AAC ATC CCC GGC GGC GGC GTC GGC ATC TTC GAC GGA TGC ACT              480
Asp Leu Asn Ile Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr
                125                 130                 135

CCC CAG TTC GGC GGT CTG CCC GGC CAG CGC TAC GGC GGC ATC TCG TCC              528
Pro Gln Phe Gly Gly Leu Pro Gly Gln Arg Tyr Gly Gly Ile Ser Ser
            140                 145                 150

CGC AAC GAG TGC GAT CGG TTC CCC GAC GCC CTC AAG CCC GGC TGC TAC              576
Arg Asn Glu Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr
        155                 160                 165

TGG CGC TTC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC              624
Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe
    170                 175                 180

CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC              672
Arg Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg
185                 190                 195                 200

CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC              720
Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser
                205                 210                 215
```

```
ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC        768
Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr
            220                 225                 230

TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC        816
Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys
        235                 240                 245

ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC        864
Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys
    250                 255                 260

ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC        912
Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr
265                 270                 275                 280

CAT CAG TGC CTG TAGACGCAGG GCAGCTTGAG GGCCTTACTG GTGGCCGCAA            964
His Gln Cys Leu
            285

CGAAATGACA CTCCCAATCA CTGTATTAGT TCTTGTACAT AATTTCGTCA TCCCTCCAGG     1024

GATTGTCACA TAAATGCAAT GAGGAACAAT GAGTAC                               1060
```

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 305 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

```
Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala Ala Leu Pro
-21 -20                 -15                 -10

Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys
 -5                  1                   5                  10

Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val Asn Gln Pro
             15                  20                  25

Val Phe Ser Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp Phe Asp Ala
         30                  35                  40

Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys Ala Asp Gln
     45                  50                  55

Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe Ala Ala Thr
 60                  65                  70                  75

Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala Cys Tyr Glu
                 80                  85                  90

Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Val Val Gln
             95                  100                 105

Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Asn
         110                 115                 120

Ile Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Pro Gln Phe
     125                 130                 135

Gly Gly Leu Pro Gly Gln Arg Tyr Gly Gly Ile Ser Ser Arg Asn Glu
140                 145                 150                 155

Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr Trp Arg Phe
                160                 165                 170
```

```
Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln Val
            175                 180                 185

Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp
        190                 195                 200

Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser Ser
    205                 210                 215

Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr
220                 225                 230                 235

Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu
                240                 245                 250

Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys
            255                 260                 265

Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln Cys
        270                 275                 280

Leu
```

(2) INFORMATION FOR SEQ ID NO: 57:
 (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 9 amino acids
  (B) TYPE: amino acid
  (C) STRANDEDNESS: single
  (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
  (A) DESCRIPTION: /desc = "Conserved region"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

```
Thr Arg Tyr Trp Asp Cys Cys Lys Pro/Thr
1               5
```

(2) INFORMATION FOR SEQ ID NO: 58:
 (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 6 amino acids
  (B) TYPE: amino acid
  (C) STRANDEDNESS: single
  (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
  (A) DESCRIPTION: /desc = "Conserved region"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

```
Trp Arg Phe/Tyr Asp Trp Phe
1                   5
```

(2) INFORMATION FOR SEQ ID NO: 59:
 (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 41 base pairs
  (B) TYPE: nucleic acid
  (C) STRANDEDNESS: single
  (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
  (A) DESCRIPTION: /desc = "Primer s"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

```
GCTGATGGCA GGTCCACIA/CG ITAC/TTGGGAC/T TGC/TTGC/TAAA/GA/C C        41
```

(2) INFORMATION FOR SEQ ID NO: 60:
 (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 29 base pairs
  (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "Primer as"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

GTCGGCGTTC TTA/GAACCAA/GT CA/GA/TAICG/TCC 29

(2) INFORMATION FOR SEQ ID NO: 61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "forward primer 1"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

TGGTTC/TAAGA ACGCCGACAA TCCG 24

(2) INFORMATION FOR SEQ ID NO: 62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "reverse primer 1"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

GCTCTAGAGC CTGCGTCTAC AGGCACTGAT 30

(2) INFORMATION FOR SEQ ID NO: 63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 93 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "forward primer 2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

CGGGATCCCA TTTATGATGG TCGCGTGGTG GTCTCTATTT CTGTACGGCC
TTCAGGTCGC GGCACCTGCT TTCGCTGCTG ATGGCAGGTC CAC 93

(2) INFORMATION FOR SEQ ID NO: 64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "reverse primer 2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GCTCTAGAGC CTGCGTCTAC AGGCACTGAT 30

(2) INFORMATION FOR SEQ ID NO: 65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 922 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: hybrid DNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..922
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

```
CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG          48
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
 1               5                  10                  15

GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG CGG TAC TGG          96
Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
            20                  25                  30

GAT TGC TGT AAG CCG TCG TGC TCG TGG CCC GGC AAG GCG CTC GTG AAC         144
Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Leu Val Asn
        35                  40                  45

CAG CCC GTC TAC GCC CGC AAC GCA AAC TTC CAG CGC ATC ACC GAC CCC         192
Gln Pro Val Tyr Ala Arg Asn Ala Asn Phe Gln Arg Ile Thr Asp Pro
    50                  55                  60

AAC GCC AAG TCC GGC TGC GAT GGC GGC TCC GCC TTC TCC TGC GCC GAC         240
Asn Ala Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asp
65                  70                  75                  80

CAG ACC CCG TGG GCC GTG AGC GAC GAC TTT GCC TAC GGT TTC GCG GCT         288
Gln Thr Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala
                85                  90                  95

ACG GCG CTC GCC GGC CAG TCC GAG TCT TCG TGG TGC TGT GCC TGC TAC         336
Thr Ala Leu Ala Gly Gln Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr
            100                 105                 110

GAA CTC ACC TTC ACT TCG GGC CCC GTT GCT GGC AAG AAG ATG GCT GTC         384
Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ala Val
        115                 120                 125

CAG TCC ACC AGC ACT GGC GGT GAC CTC GGT AGC AAC CAC TTT GAC CTC         432
Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu
    130                 135                 140

AAC ATG CCA GGT GGC GGT GTC GGC ATC TTC GAC GGC TGC TCG CCT CAG         480
Asn Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Ser Pro Gln
145                 150                 155                 160

GTT GGC GGT CTC GCC GGC CAG CGC TAT GGC GGC GTC TCG TCC CGC AGC         528
Val Gly Gly Leu Ala Gly Gln Arg Tyr Gly Gly Val Ser Ser Arg Ser
                165                 170                 175

GAA TGC GAC TCC TTC CCC GCG GCA CTC AAG CCC GGC TGC TAC TGG CGC         576
Glu Cys Asp Ser Phe Pro Ala Ala Leu Lys Pro Gly Cys Tyr Trp Arg
            180                 185                 190

TAC GAC TGG TTT AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT CAG         624
Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln
        195                 200                 205

GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC AAC         672
Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn
    210                 215                 220

GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC AGC         720
Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser
225                 230                 235                 240

TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC ACC         768
Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr
                245                 250                 255
```

```
ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT GCT        816
Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala
            260                 265                 270

GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGG TGC ACC ACC        864
Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr
        275                 280                 285

TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT CAG        912
Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln
    290                 295                 300

TGC CTG TAG  A                                                        922
Cys Leu  *
305
```

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
 1               5                  10                  15

Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
            20                  25                  30

Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Leu Val Asn
        35                  40                  45

Gln Pro Val Tyr Ala Arg Asn Ala Asn Phe Gln Arg Ile Thr Asp Pro
    50                  55                  60

Asn Ala Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asp
65                  70                  75                  80

Gln Thr Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala
                85                  90                  95

Thr Ala Leu Ala Gly Gln Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr
            100                 105                 110

Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ala Val
        115                 120                 125

Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu
    130                 135                 140

Asn Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Ser Pro Gln
145                 150                 155                 160

Val Gly Gly Leu Ala Gly Gln Arg Tyr Gly Gly Val Ser Ser Arg Ser
                165                 170                 175

Glu Cys Asp Ser Phe Pro Ala Ala Leu Lys Pro Gly Cys Tyr Trp Arg
            180                 185                 190

Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln
        195                 200                 205

Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn
    210                 215                 220

Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser
```

225 230 235 240

Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr
245 250 255

Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala
260 265 270

Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr
275 280 285

Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln
290 295 300

Cys Leu *
305

(2) INFORMATION FOR SEQ ID NO: 68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 922 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:2..922
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

C CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT 46
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu
1 5 10 15

CAG GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAC 94
Gln Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr
20 25 30

TGG GAT TGT TGT AAG CCC TCT TGC TCC TGG GGC GAC AAG GCC TCG GTC 142
Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Asp Lys Ala Ser Val
35 40 45

AGC GCC CCC GTC CTG ACC TGC GAC AAG AAC GAC AAC CCC ATC TCC GAC 190
Ser Ala Pro Val Leu Thr Cys Asp Lys Asn Asp Asn Pro Ile Ser Asp
50 55 60

GCC AAC GCC GTG AGC GGT TGC AAC GGC GGC ACT TCC TAC ACC TGC AGC 238
Ala Asn Ala Val Ser Gly Cys Asn Gly Gly Thr Ser Tyr Thr Cys Ser
65 70 75

AAC AAC TCC CCG TGG GCT GTC AAC GAC AAC CTC GCC TAT GGC TTT GCC 286
Asn Asn Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala
80 85 90 95

GCT ACC AAG CTC TCT GGA GGC TCC GAG TCC AGC TGG TGC TGT GCT TGC 334
Ala Thr Lys Leu Ser Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys
100 105 110

TAC GCT CTC ACC TTT ACG ACT GGC CCC GTG AAG GGC AAG ACC ATG GTC 382
Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val
115 120 125

GTA CAG TCC ACC AAC ACC GGA GGC GAT CTC GGC GAG AAC CAC TTC GAT 430
Val Gln Ser Thr Asn Thr Gly Gly Asp Leu Gly Glu Asn His Phe Asp
130 135 140

CTC CAG ATG CCC GGC GGC GGT GTC GGC ATC TTT GAC GGC TGC AGC TCC 478
Leu Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Ser Ser
145 150 155

```
CAG TGG GGT GGC CTC GGC GGT GCT CAG TAC GGC GGC ATC TCG TCG CGA      526
Gln Trp Gly Gly Leu Gly Gly Ala Gln Tyr Gly Gly Ile Ser Ser Arg
160                 165                 170                 175

AGC GAC TGC GAC AGC TTC CCC GAG CTG CTC AAG GAC GGC TGC TAC TGG      574
Ser Asp Cys Asp Ser Phe Pro Glu Leu Leu Lys Asp Gly Cys Tyr Trp
                180                 185                 190

CGC TAC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT      622
Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg
            195                 200                 205

CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC      670
Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg
        210                 215                 220

AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC      718
Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr
225                 230                 235

AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC      766
Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser
240                 245                 250                 255

ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT      814
Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr
                260                 265                 270

GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC ACC      862
Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr
            275                 280                 285

ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT      910
Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His
        290                 295                 300

CAG TGC CTG TAG                                                     922
Gln Cys Leu  *
    305
```

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

```
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
1               5                  10                  15

Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
            20                  25                  30

Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Asp Lys Ala Ser Val Ser
        35                  40                  45

Ala Pro Val Leu Thr Cys Asp Lys Asn Asp Asn Pro Ile Ser Asp Ala
    50                  55                  60

Asn Ala Val Ser Gly Cys Asn Gly Gly Thr Ser Tyr Thr Cys Ser Asn
65                  70                  75                  80

Asn Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala
                85                  90                  95

Thr Lys Leu Ser Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr
```

100 105 110

Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val Val
115 120 125

Gln Ser Thr Asn Thr Gly Gly Asp Leu Gly Glu Asn His Phe Asp Leu
130 135 140

Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Ser Ser Gln
145 150 155 160

Trp Gly Gly Leu Gly Gly Ala Gln Tyr Gly Gly Ile Ser Ser Arg Ser
165 170 175

Asp Cys Asp Ser Phe Pro Glu Leu Leu Lys Asp Gly Cys Tyr Trp Arg
180 185 190

Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln
195 200 205

Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn
210 215 220

Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser
225 230 235 240

Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr
245 250 255

Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala
260 265 270

Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr
275 280 285

Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln
290 295 300

Cys Leu *
305

(2) INFORMATION FOR SEQ ID NO: 69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 928 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..928
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG 48
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
1 5 10 15

GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAC TGG 96
Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
20 25 30

GAT TGC TGC AAG CCC TCT TGC TCT TGG GGC GGA AAG GCT GCT GTC AGC 144
Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Gly Lys Ala Ala Val Ser
35 40 45

GCC CCT GCT TTG ACC TGT GAC AAG AAG GAC AAC CCC ATC TCA AAC CTG 192
Ala Pro Ala Leu Thr Cys Asp Lys Lys Asp Asn Pro Ile Ser Asn Leu
50 55 60

```
AAC GCT GTC AAC GGT TGT GAG GGT GGT GGT TCT GCC TTC GCC TGC ACC      240
Asn Ala Val Asn Gly Cys Glu Gly Gly Gly Ser Ala Phe Ala Cys Thr
 65                  70                  75                  80

AAC TAC TCT CCT TGG GCG GTC AAT GAC AAC CTT GCC TAC GGC TTC GCT      288
Asn Tyr Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala
            85                  90                  95

GCA ACC AAG CTT GCC GGT GGC TCC GAG GGT AGC TGG TGC TGT GCT TGC      336
Ala Thr Lys Leu Ala Gly Gly Ser Glu Gly Ser Trp Cys Cys Ala Cys
        100                 105                 110

TAC GCA CTT ACC TTC ACC ACC GGT CCC GTC AAG GGT AAG ACC ATG GTC      384
Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val
    115                 120                 125

GTC CAG TCC ACC AAC ACT GGA GGC GAC CTC GGT GAC AAC CAC TTC GAT      432
Val Gln Ser Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp
130                 135                 140

CTT ATG ATG CCT GGT GGC GGT GTT GGA ATC TTC GAC GGT TGC ACT TCT      480
Leu Met Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Ser
145                 150                 155                 160

CAG TTC GGC AAG GCT CTC GGT GGT GCC CAG TAC GGT GGC ATC TCC TCC      528
Gln Phe Gly Lys Ala Leu Gly Gly Ala Gln Tyr Gly Gly Ile Ser Ser
            165                 170                 175

CGA AGC GAG TGC GAC AGC TTC CCT GAG ACT CTC AAG GAC GGT TGC CAT      576
Arg Ser Glu Cys Asp Ser Phe Pro Glu Thr Leu Lys Asp Gly Cys His
        180                 185                 190

TGG CGC TTC GAC TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC      624
Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe
    195                 200                 205

CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC      672
Arg Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg
210                 215                 220

CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC      720
Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser
225                 230                 235                 240

ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC      768
Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr
            245                 250                 255

TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC      816
Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys
        260                 265                 270

ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC      864
Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys
    275                 280                 285

ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC      912
Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr
290                 295                 300

CAT CAG TGC CTG TAG  A                                              928
His Gln Cys Leu  *
305
```

(2) INFORMATION FOR SEQ ID NO: 70:
  (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 309 amino acids
    (B) TYPE: amino acid

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
1 5 10 15

Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
20 25 30

Asp Cys Cys Lys Pro Ser Cys Ser Trp Gly Gly Lys Ala Ala Val Ser
35 40 45

Ala Pro Ala Leu Thr Cys Asp Lys Lys Asp Asn Pro Ile Ser Asn Leu
50 55 60

Asn Ala Val Asn Gly Cys Glu Gly Gly Gly Ser Ala Phe Ala Cys Thr
65 70 75 80

Asn Tyr Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala
85 90 95

Ala Thr Lys Leu Ala Gly Gly Ser Glu Gly Ser Trp Cys Cys Ala Cys
100 105 110

Tyr Ala Leu Thr Phe Thr Thr Gly Pro Val Lys Gly Lys Thr Met Val
115 120 125

Val Gln Ser Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp
130 135 140

Leu Met Met Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Ser
145 150 155 160

Gln Phe Gly Lys Ala Leu Gly Gly Ala Gln Tyr Gly Gly Ile Ser Ser
165 170 175

Arg Ser Glu Cys Asp Ser Phe Pro Glu Thr Leu Lys Asp Gly Cys His
180 185 190

Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe
195 200 205

Arg Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg
210 215 220

Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser
225 230 235 240

Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr
245 250 255

Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys
260 265 270

Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys
275 280 285

Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr
290 295 300

His Gln Cys Leu *

(2) INFORMATION FOR SEQ ID NO: 71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 915 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..915
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

```
ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT CAG GTC GCG      48
Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln Val Ala
  1               5                  10                  15

GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG AGG TAT TGG GAT TGT      96
Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys
            20                  25                  30

TGC AAG CCG TCA TGT GCT TGG TCC GGC AAG GCC TCA GTG TCA TCT CCC     144
Cys Lys Pro Ser Cys Ala Trp Ser Gly Lys Ala Ser Val Ser Ser Pro
        35                  40                  45

GTG CGA ACC TGT GAC GCA AAC AAC TCG CCG CTG TCC GAC GTC GAC GCA     192
Val Arg Thr Cys Asp Ala Asn Asn Ser Pro Leu Ser Asp Val Asp Ala
    50                  55                  60

AAG AGT GCG TGC GAT GGA GGC GTT GCT TAC ACT TGT TCA AAC AAC GCG     240
Lys Ser Ala Cys Asp Gly Gly Val Ala Tyr Thr Cys Ser Asn Asn Ala
65                  70                  75                  80

CCT TGG GCT GTT AAC GAT AAC CTC TCT TAT GGT TTC GCG GCC ACA GCT     288
Pro Trp Ala Val Asn Asp Asn Leu Ser Tyr Gly Phe Ala Ala Thr Ala
                85                  90                  95

ATC AAT GGC GGC AGC GAG TCT AGC TGG TGC TGT GCA TGC TAC AAG TTG     336
Ile Asn Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr Lys Leu
            100                 105                 110

ACT TTC ACG AGC GGA CCT GCT TCT GGA AAG GTC ATG GTC GTT CAA TCA     384
Thr Phe Thr Ser Gly Pro Ala Ser Gly Lys Val Met Val Val Gln Ser
        115                 120                 125

ACC AAC ACC GGG TAC GAT CTC TCT AAC AAC CAC TTT GAC ATT CTT ATG     432
Thr Asn Thr Gly Tyr Asp Leu Ser Asn Asn His Phe Asp Ile Leu Met
    130                 135                 140

CCA GGT GGC GGT GTT GGA GCG TTC GAC GGC TGC TCT AGG CAG TAC GGC     480
Pro Gly Gly Gly Val Gly Ala Phe Asp Gly Cys Ser Arg Gln Tyr Gly
145                 150                 155                 160

AGC ATC CCT GGG GAG CGA TAT GGG GGT GTC ACA TCA AGG GAC CAA TGC     528
Ser Ile Pro Gly Glu Arg Tyr Gly Gly Val Thr Ser Arg Asp Gln Cys
                165                 170                 175

GAC CAA ATG CCA AGT GCA CTC AAG CAG GGC TGC TAT TGG CGC TTC GAT     576
Asp Gln Met Pro Ser Ala Leu Lys Gln Gly Cys Tyr Trp Arg Phe Asp
            180                 185                 190

TGG TTC AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC CGT CAG GTC CAG     624
Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln Val Gln
        195                 200                 205

TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC CGC AAC GAC GAC     672
Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp Asp
    210                 215                 220

GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC ACC AGC TCT CCG     720
Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser Ser Pro
225                 230                 235                 240

GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC TCC ACC ACC TCG     768
Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr Ser
                245                 250                 255
```

```
AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC ACT GCT GAG AGG      816
Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu Arg
            260                 265                 270

TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC ACC ACC TGC GTC      864
Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys Val
        275                 280                 285

GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC CAT CAG TGC CTG      912
Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln Cys Leu
    290                 295                 300

TAG                                                                  915
*
305
```

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

```
Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln Val Ala
 1               5                  10                  15

Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys
            20                  25                  30

Cys Lys Pro Ser Cys Ala Trp Ser Gly Lys Ala Ser Val Ser Ser Pro
        35                  40                  45

Val Arg Thr Cys Asp Ala Asn Asn Ser Pro Leu Ser Asp Val Asp Ala
    50                  55                  60

Lys Ser Ala Cys Asp Gly Gly Val Ala Tyr Thr Cys Ser Asn Asn Ala
65                  70                  75                  80

Pro Trp Ala Val Asn Asp Asn Leu Ser Tyr Gly Phe Ala Ala Thr Ala
                85                  90                  95

Ile Asn Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr Lys Leu
            100                 105                 110

Thr Phe Thr Ser Gly Pro Ala Ser Gly Lys Val Met Val Val Gln Ser
        115                 120                 125

Thr Asn Thr Gly Tyr Asp Leu Ser Asn Asn His Phe Asp Ile Leu Met
    130                 135                 140

Pro Gly Gly Gly Val Gly Ala Phe Asp Gly Cys Ser Arg Gln Tyr Gly
145                 150                 155                 160

Ser Ile Pro Gly Glu Arg Tyr Gly Gly Val Thr Ser Arg Asp Gln Cys
                165                 170                 175

Asp Gln Met Pro Ser Ala Leu Lys Gln Gly Cys Tyr Trp Arg Phe Asp
            180                 185                 190

Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln Val Gln
        195                 200                 205

Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp Asp
    210                 215                 220

Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser Ser Pro
```

```
225                 230                 235                 240

Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser Thr Thr Ser
                245                 250                 255

Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu Arg
            260                 265                 270

Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys Val
        275                 280                 285

Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln Cys Leu
    290                 295                 300

*
305
```

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 925 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
- (A) NAME/KEY: CDS
- (B) LOCATION:2..925

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

```
C CCA TTT ATG ATG GTC GCG TGG TGG TCT CTA TTT CTG TAC GGC CTT          46
  Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu
    1               5                  10                  15

CAG GTC GCG GCA CCT GCT TTC GCT GCT GAT GGC AGG TCC ACG CGG TAT        94
Gln Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr
                20                  25                  30

TGG GAT TGC TGT AAG CCC AGC TGC TCC TGG CCC GAC AAG GCC CCC GTA       142
Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Asp Lys Ala Pro Val
            35                  40                  45

GGT TCC CCC GTA GGC ACC TGC GAC GCC GGC AAC AGC CCC CTC GGC GAC       190
Gly Ser Pro Val Gly Thr Cys Asp Ala Gly Asn Ser Pro Leu Gly Asp
        50                  55                  60

CCC CTG GCC AAG TCT GGC TGC GAG GGC GGC CCG TCG TAC ACG TGC GCC       238
Pro Leu Ala Lys Ser Gly Cys Glu Gly Gly Pro Ser Tyr Thr Cys Ala
    65                  70                  75

AAC TAC CAG CCG TGG GCG GTC AAC GAC CAG CTG GCC TAC GGC TTC GCG       286
Asn Tyr Gln Pro Trp Ala Val Asn Asp Gln Leu Ala Tyr Gly Phe Ala
 80                  85                  90                  95

GCC ACG GCC ATC AAC GGC GGC ACC GAG GAC TCG TGG TGC TGC GCC TGC       334
Ala Thr Ala Ile Asn Gly Gly Thr Glu Asp Ser Trp Cys Cys Ala Cys
                100                 105                 110

TAC AAG CTC ACC TTC ACC GAC GGC CCG GCC TCG GGC AAG ACC ATG ATC       382
Tyr Lys Leu Thr Phe Thr Asp Gly Pro Ala Ser Gly Lys Thr Met Ile
            115                 120                 125

GTC CAG TCC ACC AAC ACG GGC GGC GAC CTG TCC GAC AAC CAC TTC GAC       430
Val Gln Ser Thr Asn Thr Gly Gly Asp Leu Ser Asp Asn His Phe Asp
        130                 135                 140

CTG CTC ATC CCC GGC GGC GGC GTC GGC ATC TTC GAC GGC TGC ACC TCC       478
Leu Leu Ile Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Ser
    145                 150                 155
```

```
CAG TAC GGC CAG GCC CTG CCC GGC GCC CAG TAC GGC GGC GTC AGC TCC        526
Gln Tyr Gly Gln Ala Leu Pro Gly Ala Gln Tyr Gly Gly Val Ser Ser
160                 165                 170                 175

CGC GCC GAG TGC GAC CAG ATG CCC GAG GCC ATC AAG GCC GGC TGC CAG        574
Arg Ala Glu Cys Asp Gln Met Pro Glu Ala Ile Lys Ala Gly Cys Gln
                180                 185                 190

TGG CGC TAC GAT TGG TTT AAG AAC GCC GAC AAT CCG AGC TTC AGC TTC        622
Trp Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe
            195                 200                 205

CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC        670
Arg Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg
        210                 215                 220

CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC        718
Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser
    225                 230                 235

ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC        766
Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr
240                 245                 250                 255

TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC        814
Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys
                260                 265                 270

ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC        862
Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys
            275                 280                 285

ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC        910
Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr
        290                 295                 300

CAT CAG TGC CTG TAG                                                    925
His Gln Cys Leu  *
    305
```

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 308 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

```
Pro Phe Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln
  1               5                  10                  15

Val Ala Ala Pro Ala Phe Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp
             20                  25                  30

Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Asp Lys Ala Pro Val Gly
         35                  40                  45

Ser Pro Val Gly Thr Cys Asp Ala Gly Asn Ser Pro Leu Gly Asp Pro
     50                  55                  60

Leu Ala Lys Ser Gly Cys Glu Gly Gly Pro Ser Tyr Thr Cys Ala Asn
 65                  70                  75                  80

Tyr Gln Pro Trp Ala Val Asn Asp Gln Leu Ala Tyr Gly Phe Ala Ala
                 85                  90                  95

Thr Ala Ile Asn Gly Gly Thr Glu Asp Ser Trp Cys Cys Ala Cys Tyr
```

```
                100                 105                 110

Lys Leu Thr Phe Thr Asp Gly Pro Ala Ser Gly Lys Thr Met Ile Val
        115                 120                 125

Gln Ser Thr Asn Thr Gly Gly Asp Leu Ser Asp Asn His Phe Asp Leu
    130                 135                 140

Leu Ile Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Ser Gln
145                 150                 155                 160

Tyr Gly Gln Ala Leu Pro Gly Ala Gln Tyr Gly Gly Val Ser Ser Arg
                165                 170                 175

Ala Glu Cys Asp Gln Met Pro Glu Ala Ile Lys Ala Gly Cys Gln Trp
            180                 185                 190

Arg Tyr Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg
        195                 200                 205

Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg
    210                 215                 220

Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr
225                 230                 235                 240

Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr Ser
                245                 250                 255

Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr
            260                 265                 270

Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr
        275                 280                 285

Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His
    290                 295                 300

Gln Cys Leu  *
305
```

PATENT CLAIMS

1. A method for providing a novel DNA sequence encoding a polypeptide from a micro-organism with an activity of interest comprises the following steps:

i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of i nterest,

ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence,

iii) expressing said resulting hybrid DNA sequence,

iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity,

v) isolating the hybrid DNA sequence identified in step iv)

2. The method according to claim 1 wherein the PCR primers in step i) have homology to conserved regions in (a) known structural gene(s) or the polypeptide(s) thereof.

3. The method according to claim 1 wherein the PCR primers in step i) are degenerated on the basis of conserved regions in (a) known gene(s).

4. The method according to any of claims 1 to 3 wherein the PCR amplification in step i) is performed using naturally occurring DNA as template.

5. The method according to any of claims 1 to 3 wherein the microorganism has not been subjected to "in vitro" selection.

6. The method according to any of claims 1 to 5 wherein the PCR amplification in step i) is performed on a sample containing DNA from an un-isolated microorganism.

7. The method according to any of claims 1 to 6 wherein the 5' and 3' structural gene sequences originate from two different structural genes encoding polypeptides having the same activity.

8. The method according to any of claims 1 to 7 wherein the 5' structural gene sequence and the 3' structural gene sequence originate from the same structural gene sequence.

9. The method according to any of claims 1 to 8 wherein the 5' structural gene sequence and the 3' structural gene sequence originate from two different structural gene sequences encoding polypeptides having different activities.

10. The method according to any of claims 1 to 9 comprising the following steps:

i) PCR amplification of DNA from micro-organisms with PCR primers being homologous to conserved regions of a known gene encoding a polypeptide with an activity of interest,

ii) cloning the obtained PCR product into a gene encoding a polypeptide having the activity of interest, where said gene is not identical to the gene from which the PCR product is obtained, which gene is situated in an expression vector,

iii) transforming said expression vector into a suitable host cell,

iiia) culturing said host cell under suitable conditions,

iv) screening for clones comprising a DNA sequence originated from the PCR amplification in step i) encoding a polypeptide with said activity of interest or related activity,

v) isolating the DNA sequence identified in step iv).

11. The method according to claims 1 to 10, wherein the micro-organism from which DNA is to be PCR amplified in step i) is a prokaryote or an eukaryote.

12. The method according to any of claims 1 to 11, wherein the PCR amplification in step i) is performed on DNA from an un-cultivable organism.

13. The method according to claim 12, wherein the un-cultivable organism is an algae, a fungi or a protozoa.

14. The method according to claims 12 and 13, wherein said un-cultivable organism is from the group of extremophiles and plantonic marine organisms.

15. The method according to any of claims 1 to 11, wherein the PCR amplification in step i) is performed on DNA from a cultivable organism.

16. The method according to claim 15, wherein said cultivable organism is selected from the group of bacteria, fungal organisms, such as filamentous fungi or yeasts.

17. The method according to claim 16, wherein said PCR amplification in step i) is performed on one or more polynucleotides comprised in a vector, plasmid or the like, such as on a cDNA library from cultivable organisms.

18. The method according any of claims 1 to 17, wherein said activity of interest is an enzymatic activity.

19. The method according to claim 18, wherein said enzyme activity is selected from the group comprising phosphatases oxidoreductases, transferases, hydrolases, such as esterases , in particular lipases and phytases, such as glucosidases, in particular xylanases, cellulases, hemicellulases, and amylases, such as peptidases, in particular proteases, lyases, isomerases and ligases.

20. The method according to any of claims 10 to 19, wherein said host cell mentioned under iii) of claim 10 is a micro-organism, preferably a yeast or a bacteria.

21. The method according to claim 20, wherein said host cell is a yeast such as a strain of *Saccharomyces*, in particular

Saccharomyces cerevisiae.

22. The method according to claim 20, wherein said host cell is a bacteria such as a strain of *Bacillus*, in particular of *Bacillus subtilis*, or a strain *Escherichia coli*.

23. The method according to any of claims 1 to 22, wherein the clones/hybrid DNA sequences mentioned in step iv), are screened for enzymatic activity.

24. The method according to claim 23, wherein the screened clones/hybrid DNA sequences are tested for wash performance.

25. A novel DNA sequence provided according to any of the method claims 1 to 24.

26. A polypeptide with an activity of interest encoded by a DNA sequence of claim 25.


Eco RI
part A
part B
part C
e
a
b
d_{rc}
N-term 5´
3´C-term
a_{rc}
c
d
f
Sal I
1.
Eco RI
e
amplified gene
Sal I
f
2.
Eco RI
Sal I
+
Eco RI
Sal I
3.

Figure 1


PULPZYME_L
XYNA_BACCI
XYNA_BACPU
XYNA_BACST
XYNA_BACSU
XYNA_CLOAB
XYNA_CLOSR
XYNB_STRLI
XYNC_STRLI

Figure 2


PULPNS8-11 1 MRQKKLTFILAFLVCFALTLPAELLQAQIVTDN 33
PULPZYME_L 1 MRQKKLTFILAFLVCFALTLPAELEQAQIVTDN 33
PULPNS8-11 34 SLGNHDGYDYEFWKDSGGSGTMLLNHGGTFSAQ 66
PULPZYME_L 34 SLGNHDGYDYEFWKDSGGSGTMILNHGGTFSAQ 66
PULPNS8-11 67 WNNVNNILFRKGKKFNETQTHQQVGNMSINYGA 99
PULPZYME_L 67 WNNVNNILFRKGKKFNETQTHQQVGNMSINYGA 99
PULPNS8-11 100 NFQPNGNAYLCVYGWTVDPLVEYYIVDSWGNWR 132
PULPZYME_L 100 NFQPNGNAYLCVYGWTVDPLVEYYIVDSWGNWR 132
PULPNS8-11 133 PPGATPKGTLEVDGGTYDLYKHQQVNQPSIQGT 165
PULPZYME_L 133 PPGATPKGTITVDGGTYDIYETLRVNQPSIKGI 165
PULPNS8-11 166 ATFNQYWSIRQSKRTSGTVTTANHFNAWAALGM 198
PULPZYME_L 166 ATFKQYWSVRRSKRTSGTISVSNHFRAWENLGM 198
PULPNS8-11 199 NMGAFNYQIEVTEGYQSTGSANVYSNTLRINGN 231
PULPZYME_L 199 NMGKMYEVALTVEGYQSSGSANVYSNTFRENGN 231
PULPNS8-11 232 PLSTISNDKSITLDKNN 248
PULPZYME_L 232 PLSTISNDKSITLDKNN 248

Figure 3



Figure 4

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/10, 15/62, 15/56, 9/24, 9/42, C12Q 1/68 — A3

(11) International Publication Number: **WO 97/43409**

(43) International Publication Date: 20 November 1997 (20.11.97)

(21) International Application Number: PCT/DK97/00216

(22) International Filing Date: 12 May 1997 (12.05.97)

(30) Priority Data:
0562/96 10 May 1996 (10.05.96) DK

(71) Applicant *(for all designated States except US)*: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DALBØGE, Henrik [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). DIDERICHSEN, Børge [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). SANDAL, Thomas [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). KAUPPINEN, Sakari [FI/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).

(74) Common Representative: NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
26 February 1998 (26.02.98)

(54) Title: METHOD OF PROVIDING NOVEL DNA SEQUENCES

(57) Abstract

The present invention relates to a method of providing novel DNA sequences encoding a polypeptide with an activity of interest, comprising the following steps: i) PCR amplification of said DNA with PCR primers with homology to (a) known gene(s) encoding a polypeptide with an activity of interest, ii) linking the obtained PCR product to a 5' structural gene sequence and a 3' structural gene sequence, iii) expressing said resulting hybrid DNA sequence, iv) screening for hybrid DNA sequences encoding a polypeptide with said activity of interest or related activity, v) isolating the hybrid DNA sequence identified in step iv). Further, the invention also relates novel DNA sequences provided according to the method of the invention and polypeptides with an activity of interest encoded by said novel DNA sequences of the invention.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 97/00216

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/10 C12N15/62 C12N15/56 C12N9/24 C12N9/42
C12Q1/68

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 368 684 A (MEDICAL RES COUNCIL) 16 May 1990 see the whole document	1,2,4,8, 10,11, 20,25,26
X	SARANTOPOULOS S ET AL: "A METHOD FOR LINKING VL AND VH REGIONS GENES THAT ALLOWS BULK TRANSFER BETWEEN VECTORS FOR USE IN GENERATING POLYCLONAL IgG LIBRARIES" JOURNAL OF IMMUNOLOGY, vol. 152, no. 11, 1 June 1994, pages 5344-5351, XP002031702 see the whole document	1,2,4,8, 10,11, 20,25,26

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

2

Date of the actual completion of the international search	Date of mailing of the international search report
18 December 1997	22/01/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hornig, H

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	WO 91 17244 A (NOVONORDISK AS) 14 November 1991 see page 18, line 19 - page 29, line 18; figures 9,10	1-4, 8-11, 18-20, 22,25,26
A	WO 93 11249 A (NOVONORDISK AS) 10 June 1993 cited in the application see the whole document	1-26
A	B. HENRISSAT ET AL.: "A classification of glycosyl hydrolyses based on amino acid sequence similarities" BIOCHEM. J., vol. 280, 1991, THE BIOCHEM. SOCIETY, LONDON, UK, pages 309-316, XP002050142 cited in the application see the whole document	1-26
A	WO 91 17243 A (NOVONORDISK AS) 14 November 1991 cited in the application see the whole document	1-26
A	WO 94 07998 A (NOVONORDISK AS ;SCHUELEIN MARTIN (DK); FREDHOLM HENRIK (DK); HJORT) 14 April 1994 see the whole document	1-26
A	K. SMALLA ET AL.: "Rapid DNA extraction protocol from soil for polymerase chain reaction" J. APPLIED BACTERIOL., vol. 74, no. 1, 1993, BLACKWELL SCIENTIFIC PUB., OXFORD, GB, pages 78-85, XP000574302 cited in the application see the whole document	1-26
A	J.L. STEIN ET AL.: "Characterization of uncultivated procaryotes: Isolation and analysis of a 40-kilobase-pair genome fragment from a plaktonic marine archaeon" J. BACTERIOL., vol. 178, no. 3, February 1996, AM. SOC. MICROBIOL.,BALTIMORE,US;, pages 591-599, XP002050143 cited in the application see the whole document	1-26

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 96 29397 A (NOVONORDISK AS ;SCHUELEIN MARTIN (DK); ANDERSEN LENE NONBOE (DK);) 26 September 1996 cited in the application see the whole document	1-26

2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DK 97/00216

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0368684 A	16-05-90	AU 634186 B	18-02-93
		AU 4520189 A	28-05-90
		CA 2002868 A	11-05-90
		DE 68913658 D	14-04-94
		DE 68913658 T	08-09-94
		DK 164790 A	07-09-90
		ES 2052027 T	01-07-94
		WO 9005144 A	17-05-90
		JP 3502801 T	27-06-91
WO 9117244 A	14-11-91	AT 150788 T	15-04-97
		AU 652153 B	18-08-94
		AU 7791091 A	27-11-91
		DE 69125371 D	30-04-97
		DE 69125371 T	14-08-97
		EP 0531315 A	17-03-93
		ES 2100229 T	16-06-97
		US 5457046 A	10-10-95
		US 5686593 A	11-11-97
WO 9311249 A	10-06-93	BR 9206866 A	21-11-95
		EP 0618974 A	12-10-94
		FI 942644 A	03-06-94
		JP 8504560 T	21-05-96
		MX 9206979 A	01-07-93
WO 9117243 A	14-11-91	AT 118545 T	15-03-95
		AU 639570 B	29-07-93
		AU 7887491 A	27-11-91
		CA 2082279 A	10-11-91
		DE 69107455 D	23-03-95
		DE 69107455 T	12-10-95
		EP 0531372 A	17-03-93
		ES 2068586 T	16-04-95
		JP 5509223 T	22-12-93
WO 9407998 A	14-04-94	EP 0663950 A	26-07-95
		FI 951629 A	05-04-95
		JP 8501692 T	27-02-96
		MX 9306229 A	31-05-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

ernational Application No
PCT/DK 97/00216

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9629397 A	26-09-96	AU 4939496 A	08-10-96